Conditions: Homozygous Familial Hypercholesterolemia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the safety, tolerability, and efficacy of ALN-PCSSC in participants with homozygous familial hypercholesterolemia.

Detailed description:

Arms:
arm 1: 300 milligrams (mg) administered subcutaneous (SC) on Day 1. Participants with a mean serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels not suppressed by \>70% at Day 60 or Day 90, as compared to baseline, will receive a second dose at Day 90 or Day 104, respectively, based on PCSK9 levels from the previous visit. Participants also received standard of care as background therapy.

Interventions: intervention 1: ALN-PCSSC intervention 2: Standard of Care
Intervention descriptions: intervention 1: ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections. intervention 2: Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.

Protocol document:
Prot_000.pdf: 
ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
1 
Investigational New Drug 
ALN-PCSSC 
The Orion HoFH Study 
An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and 
Efficacy of ALN-PCSSC in Subjects with Homozygous Familial Hypercholesterolemia 
Protocol No.:  MDCO-PCS- 16-02 “ORION-2” 
U.S. IND No.: 127589 
EudraCT No.: 2016-003376-49 
Amended Protocol Dated: 07 November 2016 
Original Protocol Dated: 02 September 2016 
Development Phase: 
II 
Sponsor: 
The Medicines Company 
8 Sylvan Way 
Parsippany, NJ 07054 
Issue Date: 
Date: 
07 November, 2016 
CONFIDENTIAL 
Property of The Medicines Company 
May not be used, divulged, published or otherwise disclosed without the consent of 
The Medicines Company 
This study will be conducted in compliance with Good Clinical Practice (GCP) and protection of the subject 
as required by the regulations and directives in operation at this time. 


$/13&66&
&OLQLFDO6WXG\3URWRFRO0'&23&6
3URWRFRO$PHQGPHQW
7KH0HGLFLQHV&RPSDQ\
&RQILGHQWLDO

352&('85(6,1&$6(2)(0(5*(1&<
(PHUJHQF\&RQWDFW,QIRUPDWLRQ
5ROHLQ6WXG\
1DPH
7HOHSKRQH1XPEHU


$/13&66&
&OLQLFDO6WXG\3URWRFRO0'&23&6
3URWRFRO$PHQGPHQW
7KH0HGLFLQHV&RPSDQ\
&RQILGHQWLDO

35272&2/6<1236,6
1DPHRI6SRQVRU&RPSDQ\7KH0HGLFLQHV&RPSDQ\
1DPHRI)LQLVKHG'UXJ$/13&66&
1DPHRI$FWLYH,QJUHGLHQW$/1
7LWOHRI6WXG\$QRSHQODEHOVLQJOHDUPPXOWLFHQWHUSLORWVWXG\WRHYDOXDWHVDIHW\WROHUDELOLW\DQGHIILFDF\RI
$/13&66&LQVXEMHFWVZLWKKRPR]\JRXVIDPLOLDOK\SHUFKROHVWHUROHPLD
3KDVHRI'HYHORSPHQW,,
6WXG\&HQWHUV0XOWLFHQWHUVWXG\
&HQWUDO)DFLOLWLHV0
,QF
1XPEHURI6XEMHFWVVXEMHFWV
3ULQFLSDO,QYHVWLJDWRU*.HHV+R
3K'0%$
6WXG\3HULRG7KHHVWLPDWHGVWXG\SHULRGZLOOEHDSSUR[LPDWHO\PRQWKVIURPILUVWVXEMHFWHQUROOHGLQWKH
VWXG\WRODVWVXEMHFWFRPSOHWHG
2EMHFWLYHV
3ULPDU\
7RFKDUDFWHUL]HWKHHIIHFWRIDQGGD\VRIVXEFXWDQHRXV$/13&66&RQWKHSHUFHQWDJHFKDQJHIURP'D\
LQORZGHQVLW\OLSRSURWHLQFKROHVWHURO/'/&LQVXEMHFWVZLWKKRPR]\JRXVIDPLOLDOK\SHUFKROHVWHUROHPLD
6HFRQGDU\
±
7RDVVHVVWKHHIIHFWRI$/13&66&RQ
±
$EVROXWHFKDQJHDQGSHUFHQWDJHFKDQJHLQ/'/&IURP'D\WRHDFKVXEVHTXHQWYLVLWXQWLO'D\RU
ILQDOYLVLW
±
$EVROXWHFKDQJH DQGSHUFHQWDJHFKDQJHLQ3&6.
±
$EVROXWHFKDQJHDQGSHUFHQWDJHFKDQJHLQWRWDOFKROHVWHUROWULJO\FHULGHV+'/&QRQ+'/&9/'/
&$SR$$SR%DQG/SDIURP'D\WRHDFKVXEVHTXHQWYLVLWXQWLO'D\RUILQDOYLVLW
±
7RHYDOXDWHWKHVDIHW\DQGWROHUDELOLW\RI$/13&66&LQVXEMHFWVZLWKKRPR]\JRXVIDPLOLDO
K\SHUFKROHVWHUROHPLD
([SORUDWRU\
±
7RHYDOXDWHWKHIRUPDWLRQRI$QWLGUXJDQWLERGLHV$'$WR$/13&66&
±
7RDVVHVVUHVSRQVHRI/'/&E\XQGHUO\LQJFDXVDOPXWDWLRQVRIKRPR]\JRXVIDPLOLDOK\SHUFKROHVWHUROHPLD
+R)+
0HWKRGRORJ\
+\SRWKHVHV7KHSULPDU\K\SRWKHVLVLVWKDW$/13&66&ZKHQXVHGLQFRPELQDWLRQZLWKPD[LPDOO\WROHUDWHG
VWDWLQWKHUDS\ZLWKRUZLWKRXWH]HWLPLEHZLOOEHZHOOWROHUDWHGZLOOVXSSUHVV3&6.V\QWKHVLVDVVHVVHGE\WKH
UHGXFWLRQLQFLUFXODWLQJ3&6.!DQGZLOOUHVXOWLQUHGXFWLRQRI/'/&GHILQHGDVPHDQSHUFHQWFKDQJH
IURP'D\IROORZLQJGD\VDQGGD\VRIWUHDWPHQWLQVXEMHFWVZLWKKRPR]\JRXVIDPLOLDO
K\SHUFKROHVWHUROHPLD
7KLVLVDSLORWVWXG\,IWKHWULDOPHHWVDGHILQHGPHDQ/'/&UHGXFWLRQRIWKLVZLOOJXLGHWKHGHFLVLRQWR
LQLWLDWHDVXEVHTXHQWODUJHU3KDVH,,,WULDO


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
4 
Study Design:  This study will be a Phase II, open label, single arm, multicenter pilot study in subjects with 
homozygous familial hypercholesterolemia. Informed consent (and verbal assent if subject is < 18 years of age) 
will be obtained from subjects before the initiation of any study-specific procedures. 
Subjects who meet study inclusion/exclusion criteria will be instructed to continue to follow a NCEP Adult 
Treatment Panel III (or comparable) diet [Appendix C] and be required to maintain their current lipid lowering 
drug therapy for the duration of the study. 
In this study, 8-10 subjects will be enrolled and receive open label ALN-PCSSC 300mg SC. Dosing interval will 
be determined by PCSK9 level at Days 60 or 90 or rate of change of PCSK9 between Days 60 and 90. 
On Day 1, eligible subjects will be enrolled and receive the first SC administration of ALN-PCSSC. After first 
study drug administration, the subject will be observed in the clinic for at least 4 hours post injection before being 
discharged. Subjects will return at day 14 and day 30 and then at monthly intervals. If a second dose of study 
drug is deemed necessary (depending on the degree of suppression of serum PCSK9 as compared to baseline), 
subjects will receive this dose at Day 90 or 104, based on PCSK9 levels from the previous visit. 
Study visits will include collection of AE and SAE data, vital signs, ECGs, concomitant medication, and 
laboratory tests. See Section 6.1 for a detailed list of assessments. The study also includes collection of biomarker 
(pharmacodynamics) samples for efficacy and, where approved by the independent ethics committee and/or 
institutional review board (IEC/IRB) and applicable regulatory and other authorities, all subjects will be invited to 
consent to pharmacogenetics analyses, unless underlying causal mutations of HoFH are well documented by a 
validated specialized laboratory.  
Efficacy assessments will include measurement of the effects of ALN-PCSSC on levels of LDL-C, other 
lipoproteins including total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDL-C), non-
HDL-C, very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein A1 (Apo-A1), apolipoprotein B 
(Apo-B), lipoprotein(a) [Lp(a)], and PCSK9.  
Formation of anti-drug antibodies (ADA) will be assessed on Day 1 (prior to and 4 hours after the injection) and 
on subsequent visits until the end-of-study (EOS).  
The EOS visit and the last estimation of lipids will occur at Day 180.  Following Day 180 subjects will continue 
in the study until the observed LDL-C reduction is less than 20% of the absolute reduction from baseline to Day 
90. Subjects will be encouraged to complete all planned visits. The decision to initiate a Phase III study will be
defined as an observed mean 15% or greater reduction in LDL-C. A number of factors may influence the 
proportion of subjects achieving this metric, in particular the specific LDL receptor mutation(s) or other causative 
mutations of HoFH studied. Given the small sample size, such issues will be taken into careful consideration 
prior to making the final decision.  
The efficacy and safety/ tolerability data from this study will be reviewed by a Safety Committee (SC) on an 
ongoing basis, and the results will be used to guide the decision to initiate a phase III study. A recommendation 
may be taken to stop or amend the study at any of these reviews. 
Diagnosis and Main Criteria for Selection: 
Inclusion Criteria:  


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
5 
1.
Males and females, ≥ 12 years of age with a diagnosis of homozygous familial hypercholesterolemia by
genetic confirmation or a clinical diagnosis based on a history of an untreated LDL-C concentration >500
mg/dl (13 mmol/L)  together with either xanthoma before 10 years of age or evidence of heterozygous
familial hypercholesterolemia in both parents.
2.
Stable on a low-fat diet
3.
Stable on their pre-existing, lipid-lowering therapies (such as statins, cholesterol-absorption inhibitors, bile-
acid sequestrants, or combinations thereof) for at least 4 weeks with no planned medication or dose change
for the duration of study participation
4.
Fasting central lab LDL-C concentration >130 mg/dl (3.4 mmol/L) and triglyceride concentration < 400
mg/dL (4.5 mmol/L),
5.
Bodyweight of 40 kg or greater at screening.
6.
Subjects should be willing and able to give written informed consent before initiation of any study-related
procedures (if the subject is less than 18 years of age, written consent will be obtained from their guardian or
legally authorized representative, with verbal assent from the child).
Exclusion criteria: 
1.
LDL or plasma apheresis within 8 weeks prior to the screening visit, and no plan to receive it during the
study because of the attendant difficulty in maintaining stable concentrations of LDL-C while receiving
apheresis.
2.
Use of Mipomersen or Lomitapide therapy within 5 months of screening.
3.
Previous treatment with monoclonal antibodies directed towards PCSK9 within 8 weeks of screening.
4.
New York Heart Association (NYHA) class III or IV heart failure or last known left ventricular ejection
fraction < 30% or any cardiac arrhythmia within past 3 months that is not controlled by medication.
5.
Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass
graft (CABG) or stroke within 3 months of enrollment
6.
Planned cardiac surgery or revascularization
7.
Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110
mmHg despite anti-hypertensive therapy.
8.
Poorly controlled diabetes mellitus, i.e., glycated hemoglobin A1c (HbA1c) >10.0%.
9.
Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2
10. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver
or unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST), elevation > 3x the upper
limit of normal (ULN), at screening confirmed by a repeat measurement at least 1 week apart.
11. Creatine kinase (CK) > 5x ULN without a known cause
12. Other serious comorbid disease in which the life expectancy of the subject is shorter than the duration of the
trial (e.g., acute systemic infection or other serious illnesses).
13. Any history of malignant disease, with the exception of treated basal-cell carcinoma occurring >5 years
before screening.
14. Females who are pregnant or nursing, or who are of childbearing potential (includes adolescent females who
have reached menarche and are sexually active) and unwilling to use at least two methods of contraception
(e.g., oral contraceptives, barrier methods, approved contraceptive implant, long- term injectable
contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion:
a.
Women >2 years postmenopausal (defined as 1 year or longer since their last menstrual period) AND
more than 55 years of age
b.
Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test
within 24 hours of enrollment
c.
Women who are surgically sterilized at least 3 months prior to enrollment
d.
Adolescent females who have not reached menarche


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
6 
15. Males who are unwilling to use an acceptable method of birth control during the entire study period (e.g.,
condom with spermicide).
16. Known history of alcohol and/or drug abuse within 5 years.
17. Any condition that according to the investigator could interfere with the conduct of the study, such as but not
limited to:
a.
Inappropriate for this study, including subjects who are unable to communicate or to cooperate with the
investigator.
b.
Unable to understand the protocol requirements, instructions and study-related restrictions, the nature,
scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to
drug abuse or alcohol dependency).
c.
Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (e.g.,
uncooperative attitude, inability to return for follow-up visits, and improbability of completing the
study).
d.
Have any medical or surgical condition, which in the opinion of the investigator would put the subject at
increased risk from participating in the study.
e.
Involved with, or a relative of, someone directly involved in the conduct of the study.
18. Any clinically significant disease or condition affecting a major organ system, including but not limited to
gastrointestinal, renal, hepatic, endocrinologic, pulmonary, neurological, metabolic or cardiovascular disease.
19. Any surgical or medical condition which, in the judgment of the Investigator, might interfere with the
pharmacokinetics, distribution, metabolism, or excretion of the study drug (if applicable).
20. Treatment with other investigational medicinal products or devices within 30 days or 5 half-lives, whichever
is longer, prior to the administration of the study drug, planned use of investigational medicinal products or
devices.
21. Previous participation in this study or any preceding study with ALN-PCSSC.
22. Hypersensitivity to any of the ingredients of the study drug being used.
Test Drug, Dose and Mode of Administration, Batch Number(s):  
The study drug (ALN-PCSSC) will be administered by subcutaneous (SC) injection as a formulation of 
ALN-60212. It will be supplied as a sterile 100 mg vial (200 mg/mL solution) for SC injection. 
ALN-PCSSC will be administered as a single SC injection of 300mg on Day 1. If mean serum PCSK9 levels are 
not suppressed by > 70% at Day 60 or 90, as compared to baseline, a second dose of 300mg will be administered 
at the next visit at Day 90 or 104 respectively.  
Duration of Treatment: The expected duration of the subjects’ involvement in the study will be approximately 
208 days, which includes screening, study drug administration, and the follow-up period through EOS. However 
additional follow-up visits may occur every 30 days until Day 300 for subjects whose LDL-C reduction is less 
than 20% of the absolute reduction from baseline to Day 90 (for a maximum duration up to 328 days). If ALN-
PCSSC is found to be effective in lowering LDL-C in HoFH, a subsequent study may follow for subjects 
participating in the study. 
Reference Therapy, Dose and Mode of Administration:  There is no reference therapy in this study. 
Criteria for Evaluation:  


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
7 
Efficacy:   
Primary Endpoint: Percentage change in LDL-C. 
Secondary Endpoint(s): 

Absolute change and percentage change in LDL-C

Absolute change and percentage change in PCSK9 levels

Absolute change and percentage change in other total cholesterol, triglycerides, HDL-C, non-HDL-C,
VLDL-C, Apo-A1, Apo-B and Lp(a)
Exploratory Endpoint(s): 

Anti-drug antibodies (ADA) to ALN-PCSSC

Response of LDL-C reduction by underlying causal mutations of HoFH
Safety:  AEs, SAEs, vital signs, clinical laboratory values (hematology, HbA1c, coagulation testing, 
biochemistry, high sensitivity C-reactive protein (hsCRP), and urinalysis), and electrocardiograms (ECGs) will be 
collected at specified visits through to the EOS visit. In addition, ADA will be evaluated for the study drug. 
Statistical Methods:  
The primary analysis set is the modified Intent-to-Treat set (mITT), which will include all enrolled subjects who 
have received at least 1 dose of study drug. 
Unless specified otherwise, the mITT will be the default analysis set in this study. 
Summary statistics for continuous variables will include the number of subjects, mean, median, standard 
deviation or standard error, minimum and maximum. For categorical variables, the frequency and percentage will 
be given.  
The primary endpoint is the percent change from Day 1 in LDL-C following 90 and 180 days of treatment. 
Summary statistics and 95% CI of this primary endpoint will be provided. Changes of LDL-C from Day 1 by 
scheduled visits will also be summarized. Response rate of subjects with 15% or greater reduction in LDL-C from 
Day 1 following 90 and 180 days of treatment will be calculated. 
Safety summaries will include the incidence of adverse events, summaries of laboratory parameters, vital signs, 
ECGs and anti-drug antibodies. 
Sample Size 
The sample size was chosen based on clinical considerations. 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
8 
TABLE OF CONTENTS 
1. 
INTRODUCTION ......................................................................................................15 
1.1. 
Background .................................................................................................................15 
1.1.1. 
Disease Overview .......................................................................................................15 
1.1.2. 
PCSK9 Biology and Target Rationale ........................................................................15 
1.1.3. 
Mechanism of RNA Interference ................................................................................16 
1.2. 
ALN-PCSSC, an RNAi Therapeutic for Hypercholesterolemia ..................................17 
1.2.1. 
Nonclinical Studies .....................................................................................................17 
1.2.2. 
Clinical Studies ...........................................................................................................18 
1.2.3. 
Known and Potential Risks and Benefits....................................................................19 
1.3. 
Study Rationale ...........................................................................................................19 
1.4. 
Study Population .........................................................................................................20 
2. 
TRIAL OBJECTIVES AND PURPOSE ....................................................................21 
2.1. 
Primary Objective(s) ...................................................................................................21 
2.2. 
Secondary Objective(s) ...............................................................................................21 
2.3. 
Exploratory Objective(s) ............................................................................................21 
3. 
TRIAL DESIGN .........................................................................................................22 
3.1. 
Type/Design of Trial ...................................................................................................22 
3.2. 
Schematic Diagram of Trial Design ...........................................................................23 
3.3. 
Primary Endpoint ........................................................................................................23 
3.4. 
Secondary Endpoint(s) ................................................................................................23 
3.5. 
Exploratory Endpoint(s) .............................................................................................23 
3.6. 
Measures to Minimize/Avoid Bias .............................................................................23 
3.7. 
Safety Committee (SC) ...............................................................................................24 
4. 
SUBJECT POPULATION .........................................................................................25 
4.1. 
Number of Subjects ....................................................................................................25 
4.2. 
Inclusion Criteria ........................................................................................................25 
4.3. 
Exclusion Criteria .......................................................................................................25 
4.4. 
Withdrawal Criteria ....................................................................................................27 
4.4.1. 
Withdrawal from Study Medication ...........................................................................28 
5. 
TREATMENT OF SUBJECTS ..................................................................................29 
5.1. 
Study Medication ........................................................................................................29 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
9 
5.1.1. 
ALN-PCSSC ................................................................................................................29 
5.1.2. 
Packaging and Labeling ..............................................................................................29 
5.1.3. 
Storage ........................................................................................................................30 
5.1.4. 
Accountability .............................................................................................................30 
5.1.5. 
Product Complaints ....................................................................................................30 
5.2. 
Concomitant Medications ...........................................................................................31 
5.2.1. 
Required Concomitant Medication(s) and Diet ..........................................................31 
5.2.2. 
Prohibited Concomitant Medications .........................................................................31 
5.2.3. 
Permitted Concomitant Medication(s) ........................................................................32 
5.3. 
Medical Management Guidelines ...............................................................................32 
5.4. 
Restrictions .................................................................................................................32 
5.5. 
Blinding ......................................................................................................................32 
6. 
SCHEDULE AND SEQUENCE OF PROCEDURES ...............................................33 
6.1. 
Schedule of Events/Assessments ................................................................................34 
6.2. 
General Conduct of the Trial ......................................................................................36 
6.3. 
Screening Period (Days –28 to –1) .............................................................................36 
6.4. 
Enrollment (Day 1) .....................................................................................................37 
6.5. 
Follow-up Visits FU 1-6 .............................................................................................38 
6.6. 
End of Study (EOS) Visit (FU 7) ...............................................................................38 
6.7. 
Additional Follow-Up Visits (FU 8-11, if needed) ....................................................39 
7. 
PROTOCOL ASSESSMENTS ..................................................................................40 
7.1. 
Assessment of Safety ..................................................................................................40 
7.1.1. 
Adverse Events ...........................................................................................................40 
7.1.2. 
Demographics and Medical History ...........................................................................40 
7.1.3. 
Vital Signs ..................................................................................................................40 
7.1.4. 
Electrocardiograms .....................................................................................................40 
7.1.5. 
Physical Examination .................................................................................................40 
7.1.6. 
Clinical Laboratory Assessments ...............................................................................40 
7.1.7. 
Anti-ALN-PCSSC Antibodies .....................................................................................41 
7.2. 
Assessment of Efficacy ...............................................................................................41 
7.2.1. 
Change in LDL-C .......................................................................................................41 
7.2.2. 
Change in Lipids/Lipoproteins ...................................................................................42 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
10 
7.3. 
Assessment of Pharmacogenetics ...............................................................................42 
8. 
ADVERSE EVENTS..................................................................................................43 
8.1. 
Definitions ..................................................................................................................43 
8.1.1. 
Adverse Event .............................................................................................................43 
8.1.2. 
Serious Adverse Event ................................................................................................43 
8.1.3. 
Medication Errors .......................................................................................................44 
8.2. 
EVALUATING ADVERSE EVENTS .......................................................................44 
8.2.1. 
AE Severity .................................................................................................................44 
8.2.2. 
Study Drug Causality ..................................................................................................44 
8.2.3. 
Adverse Event of Special Interest (AESIs) ................................................................45 
8.2.4. 
Special Situations ........................................................................................................45 
8.3. 
PROCEDURE FOR ADVERSE EVENT REPORTING ...........................................46 
8.3.1. 
Procedure for Non-Serious Adverse Event Recording ...............................................46 
8.3.2. 
Procedure for Serious Adverse Event Reporting ........................................................46 
8.3.3. 
Procedure for Medication Error Reporting For Study Drug .......................................46 
8.3.4. 
Procedure For Reporting Adverse Events Of Special Interest (AESIs) .....................46 
8.3.5. 
Procedure For Reporting Pregnancies Exposure ........................................................47 
8.3.6. 
Procedure For Reporting Special Situations ...............................................................47 
9. 
DATA COLLECTION ...............................................................................................48 
10. 
STATISTICAL PLAN................................................................................................49 
10.1. 
Sample Size ................................................................................................................49 
10.2. 
Randomization ............................................................................................................49 
10.3. 
General Statistical Considerations and Definitions ....................................................49 
10.3.1. 
General Statistical Methods ........................................................................................49 
10.3.2. 
Analysis Populations ..................................................................................................49 
10.3.2.1. 
Modified Intent-to-Treat (mITT) Population ..............................................................49 
10.3.2.2. 
Safety Population ........................................................................................................50 
10.3.3. 
Analysis Windows and Baseline ................................................................................50 
10.3.4. 
Missing Data Handling ...............................................................................................50 
10.4. 
Statistical Analyses .....................................................................................................50 
10.4.1. 
Demographic and Background Characteristics ..........................................................50 
10.4.2. 
Study Drug and Concomitant Medications .................................................................50 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
11 
10.4.3. 
Efficacy Analysis ........................................................................................................50 
10.4.3.1. 
Primary Efficacy Endpoint .........................................................................................50 
10.4.3.2. 
Secondary Efficacy Endpoints ....................................................................................51 
10.4.3.3. 
Tertiary Efficacy Endpoints ........................................................................................51 
10.4.4. 
Safety Analysis ...........................................................................................................51 
10.4.4.1. 
Adverse Events ...........................................................................................................51 
10.4.4.2. 
Laboratory Tests .........................................................................................................51 
10.4.4.3. 
Vital Signs ..................................................................................................................51 
11. 
RECORDS RETENTION ..........................................................................................52 
12. 
QUALITY CONTROL AND QUALITY ASSURANCE .........................................53 
12.1. 
Monitoring ..................................................................................................................53 
12.2. 
Auditing ......................................................................................................................53 
12.3. 
Protocol Deviations ....................................................................................................53 
13. 
ETHICS AND RESPONSIBILITY ............................................................................55 
13.1. 
Informed Consent .......................................................................................................55 
13.2. 
Institutional Review Board/Ethics Committee ...........................................................55 
14. 
CONFIDENTIALITY ................................................................................................56 
15. 
INVESTIGATOR AGREEMENT .............................................................................57 
16. 
REFERENCES ...........................................................................................................58 
APPENDIX A. NEUROLOGICAL EXAMINATION ..............................................................61 
APPENDIX B. SAMPSON CRITERIA FOR DIAGNOSING ANAPHYLAXIS .....................65 
APPENDIX C. TLC DIET ..........................................................................................................66 
LIST OF TABLES 
Table 1: 
Investigational Product ...............................................................................................29 
Table 2: 
Common Terminology Criteria for Adverse Events (CTCAE) of Injection 
Site Reaction ...............................................................................................................45 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
12 
LIST OF ABBREVIATIONS 
ADA 
anti-drug antibodies 
AE 
adverse event 
AESI 
Adverse Event of Special Interest 
ALP 
alkaline phosphatase  
ALT 
alanine aminotransferase  
Apo-A1 
apolipoprotein A1 
Apo-B 
apolipoprotein B 
aPTT 
activated partial thromboplastin 
ASCVD 
atherosclerotic cardiovascular disease  
AST 
aspartate aminotransferase 
BUN 
total protein urea 
CABG 
coronary artery bypass graft 
CHD 
coronary heart disease 
CK 
creatine kinase 
CRP 
C-reactive protein 
CTCAE 
Common Terminology Criteria for Adverse Events 
CV 
Cardiovascular 
dL 
deciliter(s) 
EC 
Ethics Committee 
ECG 
electrocardiogram 
eCRF 
Electronic Case Report Form 
ED50 
effective dose of a drug for 50% of the population receiving the drug 
ED80 
effective dose of a drug for 80% of the population receiving the drug 
EDC 
electronic data capture 
eGFR 
estimated glomerular filtration rate 
EOS 
end of study 
FDA 
Food and Drug Administration 
GalNAc 
N-acetylgalactosamine 
GCP 
Good Clinical Practice 
GGT 
gamma glutamyl transferase 
GLP 
Good Laboratory Practice 
GPV 
Global Pharmacovigilance Department 
HbA1c 
glycated hemoglobin A1C 
HDL-C 
high density lipoprotein cholesterol 
HoFH 
homozygous familial hypercholesterolemia 
hsCRP 
high sensitivity C-reactive protein  
IB 
Investigator’s Brochure 
IC50 
concentration of the drug required for 50% inhibition in vitro 
ICH 
International Conference on Harmonisation of Technical 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
13 
Requirements for Registration of Pharmaceuticals 
IEC 
Independent Ethics Committee 
IFN-γ 
interferon-gamma 
IL6 
interleukin 6  
INR 
International normalized ratio  
IRB 
Institutional Review Board 
ISR 
Injection site reaction 
ITT 
intent-to-treat 
kg 
kilograms(s) 
LDL-C 
low density lipoprotein cholesterol 
LDLR 
low density lipoprotein receptor 
LNP 
lipid nanoparticles 
LP(a) 
lipoprotein a 
MCH 
mean cell hemoglobin  
MCHC 
mean corpuscular hemoglobin concentration 
MCV 
mean corpuscular volume 
MD 
multiple dose 
MDCO 
The Medicines Company 
MedDRA 
Medical Dictionary for Regulatory Activities 
mg 
milligram(s) 
MI 
myocardial infarction 
mITT 
Modified intent-to-treat 
mL 
milliliter(s)  
mm 
millimeter(s) 
mmHg 
millimeters of mercury 
mmol 
Millimole 
mRNA 
messenger ribonucleic acid 
NCEP 
National Cholesterol Education Program 
NHP 
nonhuman primate 
NOAEL 
no observed adverse effect level 
NYHA 
New York Heart Association 
PCI 
percutaneous coronary intervention 
PCS 
potentially clinical significant 
PCSK9 
proprotein convertase subtilisin/kexin type 9 
pH 
-log[H+] 
PT 
prothrombin time 
RBC 
red blood cells 
RNA 
ribonucleic acid 
RNAi 
ribonucleic acid interference 
SAD 
single ascending dose 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
14 
SAE 
serious adverse event 
SAP 
Statistical Analysis Plan 
SC 
Safety Committee, subcutaneous 
SD 
standard deviation 
siRNA 
small interfering ribonucleic acid 
TBIL 
total bilirubin 
TC 
total cholesterol 
TEAE 
treatment emergent adverse event 
TNF-α 
tumor necrosis factor-alpha  
TTR 
Target transthyretin 
ULN 
upper limit of normal 
USA 
United States of America 
VLDL-C 
very low density lipoprotein cholesterol 
WBC 
white blood count 
WHO 
World Health Organization 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
15 
1. 
INTRODUCTION 
This protocol describes a study to assess the safety, tolerability and efficacy of ALN-PCSSC in 
subjects with homozygous familial hypercholesterolemia (HoFH). 
This study will be conducted in compliance with Good Clinical Practices (GCP) including the 
Declaration of Helsinki and all applicable regulatory requirements. 
1.1. 
Background 
1.1.1. 
Disease Overview 
According to the World Health Organization (WHO), atherosclerotic cardiovascular disease 
(ASCVD), comprised mainly of coronary heart disease (CHD) and stroke, is the leading cause of 
death worldwide, resulting in 17 million deaths annually [WHO Cardiovascular Statistics, 2011]. 
Data from the INTERHEART case-control study estimates that 45% of myocardial infarctions 
(MI) in Western Europe and 35% of myocardial infarctions in Central and Eastern Europe are 
due to abnormalities in blood lipids [Yusef et al, 2004]. In particular, elevated LDL-C has been 
shown in multiple studies to be one of the major risk factors for CHD with a continuous and 
graded relationship between plasma LDL-C concentration and CHD risk. For every 30 mg/dL 
(0.78 mmol/L) change in LDL-C, the relative risk for CHD changes by approximately 30% 
[Grundy et al, 2004]. In addition, a large meta-analysis of 21 statin studies concluded that for 
every 1 mmol/L (39 mg/dL) reduction in LDL-C (with statin therapy) there is an approximate 
22% reduction in cardiovascular events [CTTC et al, 2010]. While statins are the treatment of 
choice for hyperlipidemia and the primary and secondary prevention of ASCVD there is still a 
need for additional lipid-lowering therapies for patients who do not reach target LDL-C levels or 
sufficient percent reductions in LDL-C to attenuate their ASCVD risk. Furthermore, in many 
patients, statin therapy cannot be optimized as patients are either intolerant of statins due to side 
effects (most commonly muscle pain, myopathy myositis) or because of other adverse effects 
such as elevations in liver enzymes. These limitations of contemporary therapy are particularly 
relevant among patients with pre-existing ASCVD such as diabetes, or patients with familial 
hypercholesterolemia who are at the highest risk of future cardiovascular (CV) events, and hence 
require the most intensive and aggressive management of hypercholesterolemia [Davidson et al, 
2005; Nag et al, 2007; Reiner et al, 2011; Stone et al, 2014]. Among these high-risk subjects, less 
than 50% achieved the target LDL-C goal of <100 mg/dL at 6 months post-statin treatment 
despite close monitoring and drug regimen optimization [Foley et al, 2003; Kearney et al, 2008; 
CTTC et al, 2010; Foody et al, 2010]. Thus, there remains a clear unmet medical need for 
lowering LDL-C, especially in certain patient populations.  
1.1.2. 
PCSK9 Biology and Target Rationale 
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a member of the subtilisin serine 
protease family. Proprotein convertase subtilisin kexin type 9 is predominantly expressed by the 
liver and is critical for the down regulation of hepatocyte low-density lipoprotein receptor 
(LDLR) expression [Mousavi et al, 2009]. LDL-C levels in plasma are markedly elevated in 
humans with gain of function mutations in PCSK9, classifying them as having severe familial 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
16 
hypercholesterolemia [Abifadel et al, 2003]. Data from genetic association studies have 
identified loss of function alleles in human PCSK9 that result in lower PCSK9 protein levels and 
lower LDL-C levels [Zhao et al, 2006; Hooper et al, 2007; Horton et al, 2009]. In one published 
study, heterozygous individuals (carrying a single copy of a loss of function PCSK9 mutation) 
had significantly lower LDL-C with median levels of approximately 70 mg/dL (1.81 mmol/L) 
[Cohen et al, 2006]. Over a 15-year period of retrospective data analysis, this sustained lowering 
in LDL-C levels translated to an 88% lower risk of risk for CHD. Follow-up publications 
describe two adult individuals who are compound heterozygous for loss of function alleles of 
PCSK9. These individuals lack detectable plasma PCSK9 protein, have LDL-C levels ≤20 
mg/dL, and yet are otherwise healthy [Zhao et al, 2006; Hooper et al, 2007]. Additionally, recent 
human clinical trials with PCSK9 blocking antibodies have shown significant lowering of LDL-
C in healthy volunteers and across a range of high CV risk populations and with elevated LDL-C 
both with and without statins [Banerjee et al, 2012; Dias et al, 2012; Milazzo et al, 2012; Raal et 
al, 2012; Roth et al, 2012; Stein et al, 2012; Sullivan et al, 2012; Hooper et al, 2013]. Thus, the 
overall scientific and clinical data suggests that PCSK9 is a well-validated drug target whose 
inhibition results in significant LDL-C lowering without otherwise negatively impacting overall 
health, most recently culminating in the approval of two monoclonal agents to inhibit PCSK9. 
1.1.3. 
Mechanism of RNA Interference 
Ribonucleic acid (RNA) interference (RNAi) is a naturally occurring cellular mechanism for 
regulating gene expression that is mediated by small interfering RNAs (siRNAs). Typically, 
synthetic siRNAs are 19-base to 25-base pair double-stranded oligonucleotides in a staggered 
duplex with a two- to four-nucleotide overhang at one or both of the 3’ ends. Such siRNAs can 
be designed to target an endogenous messenger RNA (mRNA) transcript of a given gene. When 
introduced into cells, the guide (or antisense) strand of the siRNA loads into an enzyme complex 
called the RNA-Induced Silencing Complex. This enzyme complex subsequently binds to its 
complementary mRNA sequence, mediating cleavage of the target mRNA and the suppression of 
the target protein encoded by the mRNA [Elbashir et al, 2001].  
Since unmodified siRNAs are rapidly eliminated and do not achieve significant tissue 
distribution upon systemic administration [Soutschek et al, 2004], various formulations are 
currently used to target their distribution to tissues, and to facilitate uptake of siRNAs into the 
relevant cell type. One approach that has been used successfully in vivo, in animal models 
(including in rodents and nonhuman primates [NHP]) and humans employs intravenous delivery 
of siRNA in lipid nanoparticle (LNP) formulations [Soutschek et al, 2004; Morrissey et al, 2005; 
Geisbert et al, 2006; Judge et al, 2006; Zimmermann et al, 2006; Coelho et al, 2013; Tabernero 
et al, 2013]. Another approach for liver-specific gene silencing is subcutaneously administered 
siRNA conjugated to a N-acetylgalactosamine (GalNAc) carbohydrate ligand [Ashwell and 
Morell, 1974]. Conjugation of a triantennary GalNAc ligand to an siRNA enables hepatocyte 
binding and subsequent cellular uptake via the asialoglycoprotein receptor, resulting in 
engagement of the RNAi pathway and down regulation of hepatic proteins. Single and multiple 
doses of subcutaneously administered siRNA-GalNAc conjugates have been used to target 
transthyretin (TTR) mRNA for the treatment of TTR-mediated amyloidosis. ALN-TTRCSC has 
been found to be generally safe and well tolerated in Phase I and Phase II clinical trials in over 
40 healthy volunteers and 18 subjects with familial amyloidotic cardiomyopathy and senile 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
17 
systemic amyloidosis (ALN-TTRSC-001; EudraCT 2012-004203-12; and ALN-TTRSC-002; 
EudraCT 2013-002856-33).  
1.2. 
ALN-PCSSC, an RNAi Therapeutic for Hypercholesterolemia 
ALN-PCSSC Solution for Injection (subcutaneous [SC] use) is comprised of the PCSK9 siRNA, 
ALN-60212, formulated in phosphate buffer. The PCSK9 siRNA is a chemically synthesized 
double stranded oligonucleotide covalently linked to a ligand containing GalNAc residues. This 
synthetic investigational RNAi therapeutic has been designed to suppress the liver production of 
PCSK9 when administered via SC injection. Inhibition of PCSK9 synthesis through an RNAi 
mechanism has the potential to lower tissue and circulating plasma PCSK9 protein levels, 
resulting in higher expression of LDLR in the liver, and consequently lower LDL-C levels in the 
blood stream. The initial proposed indication for ALN-PCSSC is the treatment of subjects with 
hypercholesterolemia who are not achieving therapeutic LDL-C goals despite maximally 
tolerated lipid-lowering therapy, or for subjects who are intolerant of statins. 
1.2.1. 
Nonclinical Studies 
The safety pharmacology and toxicology of ALN- PCSSC was evaluated in a series of in vitro 
and in vivo nonclinical studies. 
The drug substance in ALN-PCSSC (ALN-60212) is designed to match the human and 
cynomolgous monkey mRNA transcripts for PCSK9, sharing a substantial partial match to the 
rat PCSK9 mRNA. ALN-60212 was informatically identified from a large collection of possible 
siRNAs targeting PCSK9 based on its predicted potency and selectivity. ALN-PCSSC reduced 
the expression of PCSK9 in Hep3B liver cells with an IC50 of 20pM and inhibited hPCSK9 
serum protein levels in a Tg mouse model with a single dose ED50 of approximately 2 mg/kg and 
an ED80 dose of approximately 6 mg/kg. In single and multi-dose regimen studies in cynomolgus 
monkeys, ALN-PCSSC exhibited dose-dependent sustainable suppression of PCSK9 protein that 
was paralleled by lowering of serum LDL-C with the same kinetics. The time to reach PCSK9 
and LDL-C nadir was approximately 20 days and there was no difference in time to nadir between 
different dose levels.  In single dose studies the maximal mean PCSK9 and LDL-C inhibition was 
85% and 68%, respectively, which was observed at the two highest doses of ALN-PCSSC
administered (6 and 10 mg/kg); however, the duration of PCSK9 silencing and LDL-C lowering 
was markedly extended at the higher 10 mg/kg dose. In multi-dose studies the maximal mean 
PCSK9 and LDL-C inhibition was 93% and 74%, respectively, which was similar to those 
observed in the single dose study. Following discontinuation of ALN-PCSSC administration, 
recovery of PCSK9 levels was slow, returning to baseline after 100 days in the single dose study 
and only showing partial recovery between doses in the multi-dose regimen. There were no 
ALN-PCSSC related changes to the levels of HDL-C or triglycerides in any of the groups.  As 
expected, total cholesterol levels were reduced by up to 30% reflecting the decrease in LDL-C. 
Good Laboratory Practice (GLP) compliant repeat dose studies of 4 and 15 weeks duration have 
been conducted in rats and monkeys. These studies included toxicokinetic analysis of ALN-
PCSSC in plasma and in tissues including the liver which is the target organ, and the kidney 
which is the main organ of elimination.  


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
18 
The GLP 4 week toxicology studies in rats and monkeys involved every other week 
administration of ALN-PCSSC at dose levels of 10, 50 and 250 mg/kg and once a week 
administration of 10 mg/kg for rats and 30 mg/kg for monkeys. The GLP 15 week toxicology 
studies in rats and monkeys involved once monthly administration of ALN-PCSSC at dose levels 
of 10, 50 and 250 mg/kg and once every other week administration of 125 mg/kg for rats and 25 
mg/kg for monkeys. Each toxicology study also included an 8 week treatment free recovery 
period for all dose groups. ALN-PCSSC was well tolerated in all studies and there were no dose 
limiting toxicities. The most common findings were related to the pharmacological effects of 
ALN-PCSSC on lipid profiles. There were consistent decreases in low density lipoprotein 
cholesterol (LDL-C) and total cholesterol which were expected. Histopathological findings 
included vacuolation in hepatocytes of rats and lymph node macrophages of monkeys and the 
presence of basophilic granules in hepatocytes of monkeys and kidneys of rats. These 
microscopic findings were not associated with changes in clinical pathology parameters and are 
consistent with class effects of oligonucleotides and were not considered adverse. In a non-GLP 
dose range finding (DRF) study conducted in monkeys, ALN-PCSSC did not stimulate pro-
inflammatory cytokines, activate complement or impact coagulation. ALN-PCSSC also did not 
stimulate pro-inflammatory cytokines following single dose administration to mice. In a 
cardiovascular and respiratory study in telemetered conscious cynomolgus monkeys ALN-PCSSC 
had no immediate or delayed effects on clinical observations, qualitative or quantitative ECG 
parameters, hemodynamic parameters, respiration rate, or body temperature at any dose level. In 
addition, ALN-PCSSC did not induce gene mutations or chromosomal damage in a battery of in 
vitro and in vivo genotoxicity studies. 
Further information is in the Investigator’s Brochure (IB). 
1.2.2. 
Clinical Studies 
One Phase I study has been conducted to date (Study ALN-PCSSC -001). This was a randomized, 
single-blind, placebo-controlled, single-dose escalation and multiple-dose study of ALN-PCSSC 
administered SC to subjects with elevated LDL-C. The study was conducted in two phases: a 
single ascending dose (SAD) phase and a multiple dose (MD) phase. During the SAD phase, 
24 subjects were assigned to either receive placebo or one of five doses of ALN-PCS ranging 
from 25 mg to 800 mg. Those who received doses of at least 100 mg saw their LDL-C drop at 
least 40%; at the 500 mg dose, LDL-C levels dropped as much as 78%. At 140 days after the 
treatment was given, subjects still had an average LDL-C reduction of about 40%. 
In the MD phase, 45 subjects received multiple doses of either ALN-PCS (125mg weekly x4, 
250 mg bi-weekly x2, 300 mg and 500 mg twice given 1 month apart) or placebo. These subjects 
had maximal LDL-C reductions of 80% and average LDL-C reductions of 50% to 60%. To date, 
the drug appears to be generally safe and well tolerated. One subject on statin comedication had 
elevated liver enzymes with ALT >4x the upper limit of normal (ULN), which resolved on 
stopping the statin. 
One Phase II dose finding study (MDCO-PCS-15-01) is currently ongoing. This study is a 
placebo-controlled, double-blind, randomized trial to compare the effect of different doses of 
ALN-PCSSC given as single or multiple subcutaneous injections in subjects with high 
cardiovascular risk and elevated low-density lipoprotein cholesterol (LDL-C). Randomization 
has been completed and follow up is ongoing. An interim analysis will be performed after all 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
19 
patients have completed the Day 90 visit in order to select the dose for subsequent studies. A 
regular review of safety is performed by an independent Data Monitoring Committee and to date 
no safety concerns have been reported and no changes to the protocol have been requested. 
1.2.3. 
Known and Potential Risks and Benefits 
Subjects taking part in this clinical study will receive guideline recommended standard of care as 
background therapy (including maximally-tolerated statin therapy and/or other LDL-C lowering 
therapies ) when administered ALN-PCSSC. Reduction of LDL-C has been associated with 
reduced CV risk both by epidemiology and in controlled clinical trials. The safety profile 
observed to date is considered acceptable for this clinical trial. 
An expanded risk-benefit summary is provided in the IB. 
1.3. 
Study Rationale 
Homozygous Familial Hypercholesterolemia (HoFH) is a rare and life-threatening disease 
characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol 
(LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). The first 
major CV events often occur during adolescence, although angina pectoris, myocardial infarction 
and death have been reported in early childhood. Historically thought to affect one in a million, 
new research indicates that HoFH prevalence is likely to be higher, with as many as one in 
160,000 to 300,000 people affected. There may be as many as 40,000 people world-wide with 
HoFH. Due to the severity of the condition, early diagnosis and initiation of lipid-lowering 
treatment is critical. However, even at the highest doses of the most efficacious statins, only 
modest reductions in LDL C plasma levels, of 10-25%, are observed. Combination of statin plus 
ezetimibe can produce a further decrease in LDL-C levels of 10-15%. Combination with other 
lipid-lowering treatments such as ALN- PCSSC may therefore provide an important adjunctive 
therapy in HoFH [Cuchel et al 2014]. 
Previous studies using PCSK9-targeting siRNAs formulated in LNPs (ALN-PCS02) or using 
PCSK9 antibodies, and one Phase I study with ALN-PCSSC in which subjects received single-
doses ascending from 25 mg to 800 mg, have demonstrated that substantial lowering of PCSK9 
is safe and well-tolerated in humans. Doses for the Phase I study were calculated using the rat 
and monkey NOAELs based on body weight and body surface area (mg/m2). Collectively, the 
results of nonclinical studies with ALN-PCSSC supported a starting dose of 25 mg for subjects 
participating in the SAD phase of the previous Phase I study. 
In Phase I Study ALN-PCSSC-001, clinically significant reductions in LDL-C levels were seen 
with single ALN-PCSSC doses as low as 25 mg with larger decreases seen with higher doses and 
a plateau at 300 mg. Subjects at ALN-PCSSC doses of 300 mg or higher had maximal LDL-C 
reductions of up to 78.1% and average least squares mean group nadir reductions of 50 to 59%. 
In the MD phase, 45 subjects received multiple doses of either ALN-PCS (125 mg weekly x4, 
250 mg biweekly, 300 mg and 500 mg twice given 1 month apart) or placebo. Subjects at ALN- 
PCSSC doses of 300 mg or higher had maximal LDL-C reductions of 83% and average least 
squares mean group nadir LDL-C reductions of 53.4% to 59.9% at all dose levels tested.   
Based on the interim results of the Phase I Study ALN-PCSSC -001, where maximum effect on 
LDL-C was seen by 84 days and a significant effect was still observed at 180 days, this study has 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
20 
been designed to test the efficacy and duration of effect of 300mg of ALN- PCSSC  in subjects 
with HoFH. This will allow dose selection for a subsequent Phase III study in HoFH. The dosing 
regimens used in this study are therefore fully supported by the findings of the Phase I study. 
1.4. 
Study Population 
This study will enroll male and female subjects, ≥ 12 years of age with a diagnosis of 
homozygous familial hypercholesterolemia. 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
21 
2. 
TRIAL OBJECTIVES AND PURPOSE 
2.1. 
Primary Objective(s) 
To characterize the effect of 90 and 180 days of subcutaneous ALN-PCSSC on the percentage 
change from Day 1 in low-density lipoprotein cholesterol (LDL-C) in subjects with homozygous 
familial hypercholesterolemia 
2.2. 
Secondary Objective(s) 

To assess the effect of ALN-PCSSC on:
 Absolute change and percentage change in LDL-C from Day 1 to each subsequent
visit until Day 180 or final visit 
 Absolute change and percentage change in PCSK9 
 Absolute change and percentage change in total cholesterol, triglycerides, HDL-
C, non-HDL-C, VLDL-C, Apo-A1 Apo-B and Lp(a) from Day 1 to each 
subsequent visit until Day 180 or final visit 

To evaluate the safety and tolerability of ALN-PCSSC in subjects with homozygous
familial hypercholesterolemia
2.3. 
Exploratory Objective(s) 

To evaluate the formation of Anti-drug antibodies (ADA) to ALN-PCSSC

To assess response of LDL-C by underlying causal mutations of HoFH


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
22 
3. 
TRIAL DESIGN 
3.1. 
Type/Design of Trial 
This study will be a Phase II, open label, single arm, multicenter pilot study in subjects with 
homozygous familial hypercholesterolemia.  Informed consent (and verbal assent if subject is 
< 18 years of age) will be obtained from subjects before the initiation of any study-specific 
procedures.   
Subjects who meet study inclusion/exclusion criteria will be instructed to continue to follow a 
National Cholesterol Education Program (NCEP) Adult Treatment Panel III (or comparable) diet 
[Appendix C] and will be required to maintain their current lipid lowering drug therapy for the 
duration of the study. 
In this study, 8-10 subjects will be enrolled and receive open label ALN-PCSSC 300mg SC. 
Dosing interval will be determined by PCSK9 level at Day 60 or 90 or rate of change of PCSK9 
between Days 60 and 90.  
On Day 1, eligible subjects will be enrolled and receive the first SC administration of ALN-
PCSSC. After first study drug administration, the subject will be observed in the clinic for at least 
4 hours post injection before being discharged. Subjects will return at Day 14 and Day 30 and 
then at monthly intervals. If a second dose of study drug is deemed necessary (if mean serum 
PCSK9 levels are not suppressed by > 70% at Day 60 or 90, as compared to baseline), subjects 
will receive this dose at Day 90 or 104 respectively, based on PCSK9 levels from the previous 
visit. 
Study visits will include collection of AE and SAE data, vital signs, ECGs, concomitant 
medication, and laboratory tests. See Section 6.1 for a detailed list of assessments. The study also 
includes collection of biomarker samples and, where approved by the independent ethics 
committee and/or institutional review board (IEC/IRB) and applicable regulatory and other 
authorities, all subjects will be invited to consent to pharmacogenetics analyses, unless 
underlying causal mutations of HoFH are well documented by a validated specialized laboratory.  
Efficacy assessments will include measurement of the effects of ALN-PCSSC on levels of LDL-
C, other lipoproteins including total cholesterol (TC), triglycerides, high-density lipoprotein 
cholesterol (HDL-C), non-HDL-C, very low-density lipoprotein cholesterol (VLDL-C), 
apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), lipoprotein(a) [Lp(a)], and PCSK9.  
Formation of anti-drug antibodies (ADA) will be assessed on Day 1 (prior to and 4 hours after 
the injection) and on subsequent visits until the end-of-study (EOS).  
The EOS visit and the last estimation of lipids will occur at Day 180. Following Day 180 
subjects will continue in the study until the observed LDL-C reduction is less than 20% of the 
absolute reduction from baseline to Day 90. Subjects will be encouraged to complete all planned 
visits.  
The decision to initiate a Phase III study will be defined as an observed mean 15% or greater 
reduction in LDL-C. A number of factors may influence the proportion of subjects achieving this 
metric, in particular the specific LDL receptor mutation(s) or other causative mutations of HoFH 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02 
The Medicines Company 
Confidential 
23 
studied. Given the small sample size for this part of the study, such issues will be taken into 
careful consideration prior to making the final decision.  
The efficacy and safety/ tolerability data from this study will be reviewed by a Safety Committee 
(SC) on an ongoing basis, and the results will be used to guide the decision to initiate a Phase III 
study. A recommendation may be taken to stop or amend the study at any of these reviews. 
3.2. 
Schematic Diagram of Trial Design 
3.3. 
Primary Endpoint  
The primary endpoint of this trial is percentage change in LDL-C. 
3.4. 
Secondary Endpoint(s)  
The secondary endpoints of this trial are: 

Absolute change and percentage change in LDL-C

Absolute change and percentage change in PCSK9 levels

Absolute change and percentage change in total cholesterol, triglycerides, HDL-C,
non-HDL-C, VLDL-C, Apo-A1, Apo-B, and Lp(a)
3.5. 
Exploratory Endpoint(s)  
The exploratory endpoints of this trial are: 

Anti-drug antibodies (ADA) to ALN-PCSSC

Response of LDL-C reduction by underlying causal mutations of HoFH
3.6. 
Measures to Minimize/Avoid Bias  
This is an unblinded, open label study.  The primary endpoint is based on an assessment of LDL-
C, which is a measurement that is not likely to be subject to interpretation bias.    


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
24 
3.7. 
Safety Committee (SC) 
A Safety Committee (SC) will review efficacy and safety data and serious adverse events on an 
ongoing basis, and the results will be used to guide the decision to initiate a Phase III study. A 
recommendation may be taken to stop or amend the study at any of these reviews. 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
25 
4. 
SUBJECT POPULATION 
4.1. 
Number of Subjects  
In this study, 8-10 subjects will be enrolled at 2-5 multi-national centers. 
4.2. 
Inclusion Criteria 
Subjects may be included in the study if they meet all of the following criteria: 
1. Males and females, ≥ 12 years of age with a diagnosis of homozygous familial
hypercholesterolemia by genetic confirmation or a clinical diagnosis based on a history of
an untreated LDL-C concentration >500 mg/dl (13 mmol/L)  together with either
xanthoma before 10 years of age or evidence of heterozygous familial
hypercholesterolemia in both parents.
2. Stable on a low-fat diet.
3. Stable on their pre-existing, lipid-lowering therapies (such as statins, cholesterol-
absorption inhibitors, bile-acid sequestrants, or combinations thereof) for at least 4 weeks
with no planned medication or dose change for the duration of study participation.
4. Fasting central lab LDL-C concentration >130 mg/dl (3.4 mmol/L) and triglyceride
concentration < 400 mg/dL (4.5 mmol/L).
5. Bodyweight of 40 kg or greater at screening.
6. Subjects should be willing and able to give written informed consent before initiation of
any study-related procedures (if the subject is less than 18 years of age, written consent
will be obtained from their guardian or legally authorized representative, with verbal
assent from the child). The subject should be willing to comply with all required study
procedures.
4.3. 
Exclusion Criteria 
Subjects will be excluded from the study if any of the following exclusion criteria apply prior to 
enrollment: 
1. LDL or plasma apheresis within 8 weeks prior to the screening visit, and no plan to
receive it during the study because of the attendant difficulty in maintaining stable
concentrations of LDL-C while receiving apheresis.
2. Use of Mipomersen or Lomitapide therapy within 5 months of screening.
3. Previous treatment with monoclonal antibodies directed towards PCSK9 within 8 weeks
of screening.
4. New York Heart Association (NYHA) class III or IV heart failure or last known left
ventricular ejection fraction < 30% or any cardiac arrhythmia within past 3 months that is
not controlled by medication.
5. Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),
coronary artery bypass graft (CABG) or stroke within 3 months of enrollment.


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
26 
6. Planned cardiac surgery or revascularization.
7. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood
pressure >110 mmHg prior to enrollment despite anti-hypertensive therapy.
8. Poorly controlled diabetes mellitus, i.e., glycated hemoglobin A1c (HbA1c) >10.0% prior
to enrollment.
9. Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2.
10. Active liver disease defined as any known current infectious, neoplastic, or metabolic
pathology of the liver or unexplained alanine aminotransferase (ALT), aspartate
aminotransferase (AST), elevation > 3x the upper limit of normal (ULN), at screening
confirmed by a repeat measurement at least 1 week apart.
11. Creatine kinase (CK) > 5x ULN without a known cause.
12. Other serious comorbid disease in which the life expectancy of the subject is shorter than
the duration of the trial (e.g., acute systemic infection, or other serious illnesses).
13. Any history of malignant disease, with the exception of treated basal-cell carcinoma
occurring >5 years before screening.
14. Females who are pregnant or nursing, or who are of childbearing potential (includes
adolescent females who have reached menarche and are sexually active) and unwilling to
use at least two methods of contraception (e.g., oral contraceptives, barrier methods,
approved contraceptive implant, long- term injectable contraception, intrauterine device)
for the entire duration of the study. Exemptions from this criterion:
a.
Women >2 years postmenopausal (defined as 1 year or longer since their last
menstrual period) AND more than 55 years of age
b. Postmenopausal women (as defined above) and less than 55 years old with a negative
pregnancy test within 24 hours of enrollment
c.
Women who are surgically sterilized at least 3 months prior to enrollment
d. Adolescent females who have not reached menarche
15. Males who are unwilling to use an acceptable method of birth control during the entire
study period (e.g., condom with spermicide).
16. Known history of alcohol and/or drug abuse within 5 years.
17. Any condition that according to the investigator could interfere with the conduct of the
study, such as but not limited to:
a.
Inappropriate for this study, including subjects who are unable to communicate or to
cooperate with the investigator.
b. Unable to understand the protocol requirements, instructions and study-related
restrictions, the nature, scope, and possible consequences of the study (including
subjects whose cooperation is doubtful due to drug abuse or alcohol dependency).
c.
Unlikely to comply with the protocol requirements, instructions, and study-related
restrictions (e.g., uncooperative attitude, inability to return for follow-up visits, and
improbability of completing the study).


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
27 
d. Have any medical or surgical condition, which in the opinion of the investigator
would put the subject at increased risk from participating in the study.
e.
Involved with, or a relative of, someone directly involved in the conduct of the study.
18. Any clinically significant disease or condition affecting a major organ system, including
but not limited to gastrointestinal, renal, hepatic, endocrinologic, pulmonary,
neurological, metabolic or cardiovascular disease.
19. Any surgical or medical condition which, in the judgment of the Investigator, might
interfere with the pharmacokinetics, distribution, metabolism, or excretion of the study
drug (if applicable).
20. Treatment with other investigational medicinal products or devices within 30 days or 5
half-lives, whichever is longer, prior to the administration of the study drug/device,
planned use of investigational medicinal products or devices.
21. Previous participation in this study or any preceding study with ALN-PCSSC.
22. Hypersensitivity to any of the ingredients of the study drug being used.
Subjects excluded for any of the above reasons may not be re-screened for participation at any 
time if the exclusion characteristic has changed. 
4.4. 
Withdrawal Criteria 
All subjects have the right to withdraw at any point during treatment without prejudice.  The 
investigator can discontinue any subject at any time if medically necessary. It will be 
documented whether or not each subject completed the clinical study. If for any subject study 
treatment or observations were discontinued, the reason will be recorded and the Sponsor should 
be notified promptly. Reasons that a subject may discontinue participation in a clinical study are 
considered to constitute one of the following: 

Adverse event(s)

Death

Subject withdrew consent

Physician decision

Lost to follow-up
Upon occurrence of a serious or intolerable AE, the investigator or designee will make every 
possible attempt to confer with the Sponsor and the SC before discontinuing the subject. 
It is imperative to obtain complete follow-up data for all subjects whether or not they receive 
their study treatment or have discontinued ALN-PCSSC. All data collected up until the time of 
subject withdrawal is to be entered into the electronic case report form (eCRF).  In addition, 
every attempt should be made to collect follow-up information except for those subjects who 
specifically withdraw consent to release of such information.  All procedures and laboratory 
specimens or tests requested for evaluation following administration of ALN-PCSSC should be 
carried out when possible whether or not a subject continues to receive treatment according the 
protocol. Subjects will not be replaced in this trial. 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
28 
4.4.1. 
Withdrawal from Study Medication 
In the event a subject withdraws or is withdrawn from the study medication (eg, receives first 
injection and not second injection if indicated), the investigator will inform the Medical Monitor 
and the Sponsor immediately. If there is a medical reason for withdrawal, the subject will remain 
under the supervision of the investigator for protocol-specified safety follow up procedures. The 
SC may be notified.  
It is imperative to obtain complete follow-up data for all enrolled subjects whether or not they 
receive their treatment or have discontinued study drug. 


$/13&66&
&OLQLFDO6WXG\3URWRFRO0'&23&6
3URWRFRO$PHQGPHQW
7KH0HGLFLQHV&RPSDQ\
&RQILGHQWLDO


75($70(172)68%-(&76

6WXG\0HGLFDWLRQ

$/13&66&
$/13&66&LVDV\QWKHWLFFKHPLFDOO\PRGLILHGVPDOOLQWHUIHULQJULERQXFOHLFDFLGVL51$
WDUJHWLQJSURSURWHLQFRQYHUWDVHVXEWLOLVLQNH[LQW\SH3&6.PHVVHQJHUULERQXFOHLFDFLG
P51$>$/1@ZLWKDFRYDOHQWO\DWWDFKHGWULDQWHQQDU\1DFHW\OJDODFWRVDPLQH*DO1$F
OLJDQG6WXG\GUXJ$/13&66&LQIRUPDWLRQLVGHVFULEHGEHORZ
7DEOH
,QYHVWLJDWLRQDO3URGXFW
3URGXFW1DPH
$/13&66&
'RVDJH)RUP
6ROXWLRQIRU,QMHFWLRQ
8QLW'RVH
PJYLDOPJP/
5RXWHRI$GPLQLVWUDWLRQ
6&XVH
3K\VLFDO'HVFULSWLRQ
&OHDUFRORUOHVVWRSDOH\HOORZVROXWLRQ
HVVHQWLDOO\IUHHRISDUWLFXODWHV
6WXG\GUXJSUHSDUDWLRQ7KHSKDUPDFLVWRUGHVLJQHHZLOOSUHSDUHWKHVWXG\GUXJXQGHUDVHSWLF
FRQGLWLRQV2QVWXG\GUXJGRVLQJGD\VWKHSKDUPDFLVWRUGHVLJQHHZLOOZLWKGUDZWKHUHTXLUHG
DPRXQWRIVWXG\GUXJLQWRRQHV\ULQJHWREHDGPLQLVWHUHGWRWKHVXEMHFWRQWKDWGD\7KH
SURFHGXUHIRUSUHSDULQJVWXG\GUXJDQGWKHYROXPHWREHORDGHGLQWRWKHV\ULQJHLVSURYLGHGLQ
WKH3KDUPDF\0DQXDO
6WXG\GUXJDGPLQLVWUDWLRQ6XEMHFWVZLOOEHDGPLQLVWHUHG$/13&66&PJE\6&LQMHFWLRQ
6WXG\GUXJLQMHFWLRQZLOOEHDGPLQLVWHUHGE\TXDOLILHGFOLQLFDOVWXG\VLWHVWDIIXQGHUWKH
VXSHUYLVLRQRIWKHLQYHVWLJDWRURUGHVLJQHHDQGWKHLQMHFWLRQVLWHZLOOEHPDUNHGDQGPDSSHGIRU
ODWHUREVHUYDWLRQ7KHVLWHRILQMHFWLRQLVWKHDEGRPHQ,IPRUHWKDQRQHLQMHFWLRQLVQHFHVVDU\
WKHILUVWRQ'D\VKRXOGEHRQRQHVLGHRIWKHDEGRPHQDQGWKHVHFRQGRQ'D\RURQWKH
RSSRVLWHVLGHRIWKHDEGRPHQ'RQRWLQMHFWLQWRDUHDVRIDFWLYHVNLQGLVHDVHRULQMXU\VXFKDV
VXQEXUQVVNLQUDVKHVLQIODPPDWLRQRUVNLQLQIHFWLRQV
,IDORFDOUHDFWLRQDURXQGWKHLQMHFWLRQVLWHRFFXUVSKRWRJUDSKVRIWKHLQMHFWLRQVLWHVKRXOGEH
REWDLQHGDWILUVWSUHVHQWDWLRQDQGDWHDFKRIWKHIROORZXSYLVLWVXQWLOWKHLQMHFWLRQVLWHUHDFWLRQ
UHVROYHV,QMHFWLRQVLWHUHDFWLRQVPXVWEHUHSRUWHGDVGHVFULEHGLQ6HFWLRQ'HWDLOHG
LQVWUXFWLRQVIRUVWXG\GUXJDGPLQLVWUDWLRQDUHIRXQGLQWKH3KDUPDF\0DQXDO

3DFNDJLQJDQG/DEHOLQJ
6WXG\GUXJZLOOEHSURYLGHGE\&DWDOHQW3KDUPD6ROXWLRQV0HGLFDWLRQODEHOVZLOOFRPSO\ZLWK
UHJXODWRU\UHTXLUHPHQWV7KHVWRUDJHFRQGLWLRQVIRUWKHVWXG\GUXJZLOOEHGHVFULEHGRQWKH
PHGLFDWLRQODEHO


$/13&66&
&OLQLFDO6WXG\3URWRFRO0'&23&6
3URWRFRO$PHQGPHQW
7KH0HGLFLQHV&RPSDQ\
&RQILGHQWLDO

7KH$/13&66&6ROXWLRQIRU,QMHFWLRQVXEFXWDQHRXVXVHLVSDFNDJHGLQP/JODVVYLDOVZLWK
DILOOYROXPHRIQROHVVWKDQP/7KHFRQWDLQHUFORVXUHV\VWHPFRQVLVWVRID7\SH,JODVV
YLDOD7HIORQIDFHGPPVWRSSHUDQGDIOLSRIIDOXPLQXPVHDO

6WRUDJH
$/13&66&ZLOOEHVWRUHGLQDVHFXUHUHIULJHUDWRURUDWWKHDSSURSULDWHFRQGLWLRQVDVVSHFLILHGLQ
WKH3KDUPDF\0DQXDO$FFHVVVKRXOGEHVWULFWO\OLPLWHGWRWKHLQYHVWLJDWRUSKDUPDFLVWVDQG
WKHLUGHVLJQHHV1RVSHFLDOSURFHGXUHVIRUWKHVDIHKDQGOLQJRI$/13&66&DUHUHTXLUHG

$FFRXQWDELOLW\
7KHLQYHVWLJDWRURUGHVLJQHHPXVWPDLQWDLQDQLQYHQWRU\UHFRUGRIVWXG\GUXJUHFHLYHGDQG
DGPLQLVWHUHGWRDVVXUHWKHUHJXODWRU\DXWKRULWLHVDQGWKH6SRQVRUWKDWWKHVWXG\GUXJZLOOQRWEH
GLVSHQVHGWRDQ\SHUVRQZKRLVQRWDVXEMHFWXQGHUWKHWHUPVDQGFRQGLWLRQVVHWIRUWKLQWKLV
SURWRFRO6WXG\GUXJDFFRXQWDELOLW\IRUPVDQGRUVSHFLILFLQVWUXFWLRQVFDQEHIRXQGLQWKH
3KDUPDF\0DQXDO
7KHVWXG\GUXJVXSSOLHGIRUXVHLQWKLVVWXG\LVWREHSUHVFULEHGRQO\E\WKHSULQFLSDOLQYHVWLJDWRU
RUGHVLJQDWHGVXELQYHVWLJDWRUVDQGPD\QRWEHXVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWRXWOLQHGLQ
WKLVSURWRFRO
'XULQJWKHVWXG\DOOXVHGVWXG\GUXJFRQWDLQHUVHJHPSW\YLDOVERWWOHVZLOOEHNHSWXQWLOWKH
PRQLWRUKDVUHYLHZHGWKHDFFRXQWDELOLW\UHFRUGV
$OOXQXVHGVWXG\GUXJZLOOEHGHVWUR\HGRQVLWHRUUHWXUQHGWRWKHSDFNDJLQJDQGODEHOLQJIDFLOLW\
IRUGHVWUXFWLRQLIGHVWUXFWLRQRQVLWHLVQRWSRVVLEOHRQFHWKHVWXG\GUXJKDVEHHQLQYHQWRULHGDQG
WKHPRQLWRUKDVUHYLHZHGWKHDFFRXQWDELOLW\UHFRUGV,QWKHHYHQWWKDWWKHVWXG\GUXJQHHGVWREH
UHWXUQHGIRUDQ\RWKHUUHDVRQWKHVLWHZLOOUHFHLYHDZULWWHQUHTXHVWOLVWLQJWKHGUXJORWQXPEHUV
WREHUHWXUQHGDQGWKHUHDVRQIRUWKHUHWXUQUHTXHVW

3URGXFW&RPSODLQWV
6LWHVDUHUHTXLUHGWRUHSRUWDQ\SURGXFWFRPSODLQWVWR0'&2LPPHGLDWHO\EXWQRODWHUWKDQ
KRXUVIURPWKHWLPHRIDZDUHQHVVE\SKRQHRUHPDLODVIROORZV
3URGXFW&RPSODLQW,VGHILQHGDVDQ\ZULWWHQHOHFWURQLFRURUDOFRPPXQLFDWLRQWKDWDOOHJHV
GHILFLHQFLHVUHODWHGWRWKHLGHQWLW\GXUDELOLW\UHOLDELOLW\TXDOLW\VDIHW\HIIHFWLYHQHVVRU
SHUIRUPDQFHRIDSURGXFWDIWHULWLVUHOHDVHGIRUGLVWULEXWLRQ(8',5(&'HULYHG
IURP5HI86&)5


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
31 
There are two types of Product Complaints: 
Technical Quality Complaints: A report of dissatisfaction with product with regard to its 
efficacy, strength, integrity, purity, or quality; thus a potential failure to meet product 
specifications. Examples include: 

An indication that there is an unexpected physical change in the drug product such as
discoloration, change in shape of the drug product, presence of particulates or any
other physical change that might indicate contamination, a manufacturing defect or
any other event that might indicate a compromise in product quality.

An indication that the content does not meet its labeled volume, count, etc.

An indication that there is an unexpected physical change in any part of the container
(this includes the bottle, any part of the seal, the cap or the label).

An indication that the product is mislabeled.

An indication that there is an unexpected physical change of the product or container
once the product is diluted or reconstituted (the container includes the vial, bag, IV
line, syringe or any other item that is in contact with the product).

An indication that the product is falsified, tampered with or adulterated.

An indication that the product did not meet its pharmacologic effect, i.e. lack of
efficacy.

Medical Device Incidents
Preference Complaints: A report of dissatisfaction with service, delivery, packaging or other 
preference. 
5.2. 
Concomitant Medications 
5.2.1. 
Required Concomitant Medication(s) and Diet 
Subjects who meet inclusion/exclusion criteria will be instructed to continue to follow a NCEP 
Adult Treatment Panel III (or comparable) diet and be required to maintain their current lipid 
lowering drug therapy for the duration of the study. 
5.2.2. 
Prohibited Concomitant Medications  
The following medications/treatments are not permitted to be added during the study: 

Medications used to lower LDL-C (eg, statins, ezetimibe, lomitapide, mipomersen,
niacin, colesevelam, bile acid absorption inhibitors, monoclonal antibodies directed
towards PCSK9).


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
32 
5.2.3. 
Permitted Concomitant Medication(s)  
The following medications/treatments are permitted during the study: 

Hormone replacement therapy

Lipid-lower medications; subjects on lipid-lower medications (such as statins and/or
ezetimibe) should be on a stable dose for ≥30 days before screening with no planned
medication or dose change during study participation

Prescription medications prescribed to treat pre-existing medical conditions such as
diabetes and hypertension

Prescription or nonprescription medications, when necessary to treat an AE, at the
discretion of the investigator
5.3. 
Medical Management Guidelines 
If a local reaction around the injection site occurs, photographs of the injection site should be 
obtained at first presentation and at each of the follow-up visits until the injection site reaction 
resolves. Injection site reactions must be reported as described in Section 8.2.3. Detailed 
instructions for study drug administration are found in the Pharmacy Manual.  
5.4. 
Restrictions  
Subjects will have to comply with the following restrictions during the study: 

Fasted for at least 8 hours for all visits for fasting lipids and glucose blood samples

Blood donation will not be allowed at any time during the study

Must refrain from unaccustomed strenuous physical exercise for 48 hours before the
screening and any study visit until the follow-up has been completed
5.5. 
Blinding  
Not applicable, this is not a blinded study. 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
33 
6. 
SCHEDULE AND SEQUENCE OF PROCEDURES 
The Schedule of Events/Assessments (Section 6.1) summarizes the study assessments by time 
point.  
This study consists of four periods:  Screening, Treatment, End of Study and Additional Follow-
up.   

The Screening period occurs prior to administration of study drug and consists of
confirming eligibility.

The Treatment period occurs from the time of enrolling the subject, collecting Day 1
assessments and study drug administration through Day 90/104.

The End of Study visit occurs at Day 180.

The Additional Follow-up period (if necessary) occurs from end of study through Day
300. 

The maximum duration of a subject’s participation is from screening/informed
consent to end of study (last follow-up) and is expected to be up to 328 days.


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
 Protocol Amendment 1
The Medicines Company 
Confidential 
34 
6.1. 
Schedule of Events/Assessments 
Screening 
Treatment Phase 
End of 
Study (EOS) 
Additional Follow-Up p 
Study Day 
-28 to -1 
Day 
1 
FU1 
Day 14 
(± 2d) 
FU2 
Day 30 
(± 3d) 
FU3 
Day 60 
(± 3d) 
FU4 
Day 90 
(± 3d) 
Dose 2? a 
FU4X 
Day 104 
(± 3d) 
Dose 2? a 
FU5 
Day 120 
(± 3d) 
FU6 
Day 150 
(± 3d) 
FU7 
Day 180 
(± 3d) 
FU8 (Day 210) (± 3) 
FU9 (Day 240) (± 3) 
FU10 (Day 270) (± 3) 
FU11 (Day 300) (± 3) 
Informed consent 
X 
Medical History and prior 
meds 
X 
Physical Examination & 
full neurologic exam 
X 
X 
Inclusion / Exclusion 
Criteria 
X 
X 
Pharmacogenetic sample o 
X 
Enrollment 
X 
Vital Signs b 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
12 Lead ECG c 
X 
X 
Hematology, 
Coagulation d,  f 
X 
X
X 
X 
X 
X 
X 
X 
X 
X 
X 
Biochemistry, 
Inflammatory markers d, f 
X 
X
X 
X 
X 
X 
X 
X 
X 
X 
X 
HbA1c 
X 
X 
X 
X 
X n 
Urinalysis e,  
X 
X g
X 
X 
Pregnancy test e, h 
X 
X h 
X 
X 
X 
X h 
X h 
X 
X 
X 
X i 
ADA antibodies j 
X j, k 
X 
X k 
X k 
 X k 
Lipids / lipoproteins m 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Biomarker (stored 
samples)q 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Study drug admin 
X 
X a 
X a 
Concomitant medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
AE reporting 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
SAE reporting 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 


ALN-PCSSC 
Clinical Study Protocol MDCO-PCS-16-02
Protocol Amendment 1
The Medicines Company 
Confidential 
35 
ADA = anti-drug antibodies; AE = adverse event; ECG = electrocardiogram; FU=follow-up; EOS = end of study; hsCRP=high sensitivity C-reactive protein; 
IL6=interleukin 6; IFN-γ=interferon gamma; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9; SAE = 
serious adverse event; TNF-α=tumor necrosis factor alpha. 
a Day 104 visit only for those subjects who receive a second dose of study drug. Dose #2 may be given at Day 90 or 104 depending on PCSK9 levels as compared 
to baseline 
b Vital signs: blood pressure and heart rate will be measured prior to injection and at 4 hours after injection. 
c ECG is performed prior to the injection on Day 1. 
d Hematology, chemistry (including lactate, bicarbonate, glucose, HbA1c, liver and renal function, hsCRP, IL6, IFN-γ, and TNF-α), and coagulation testing. 
Blood samples for determination of laboratory values will be performed prior to study drug injection where relevant. All laboratory testing will be performed 
with subjects in a fasted state.  
e Lab tests performed in participating institution’s laboratory. Results must be available before the start of study drug injection on Day 1 to confirm subjects meet 
eligibility criteria. 
f Lab tests performed by study’s designated Central Lab facility from enrollment to EOS. In addition, subjects in whom LDL-C reduction is less than 20% of the 
absolute reduction from baseline to Day 90 will continue to be followed up on a monthly visit schedule either until this level has been reached or until Day 
300.  
g Urinalysis collection is prior to the injection on Day 1.
h Urine pregnancy test performed at each visit for females of childbearing potential. In addition, postmenopausal women who are less than 55 years of age will 
have a pregnancy test within 24 hours of enrollment and prior to any study drug injection.  Results must be available prior to the injection on Day 1 and, if a 
second dose of study drug is required, on Day 90/104. 
i Females of childbearing potential will have a pregnancy test at each additional follow-up visit until LDL-C reduction is less than 20% of the absolute reduction 
from baseline to Day 90. 
j Two ADA samples will be drawn on Day 1: one before the injection and one 4 hours after the injection. 
k Additional aliquots of plasma and serum will be collected at each time point and stored for future analyses. 
l For subjects in whom LDL-C reduction is less than 20% of the absolute reduction from baseline to Day 90, formation of ADA will be assessed at the last visit. 
m Efficacy parameters (Lipids / lipoproteins) will include LDL-C, total cholesterol, triglycerides, HDL-C, non-HDL-C, very low-density lipoprotein (VLDL-C), 
apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), lipoprotein(a) [Lp(a)], and PCSK9. 
n Day 270 only. 
o Sample may be taken during screening or anytime during study to be processed and stored, but only after separate consent has been signed.
p Additional Follow-Up visits only for those subjects in whom LDL-C reduction is less than 20% of the absolute reduction from baseline to Day 90. 
q 3 aliquots of plasma and 3 aliquots of serum will be stored for efficacy and safety biomarker analysis if needed. All samples will be destroyed 1 year following 
the last subject's last visit in the study. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
36 
6.2. 
General Conduct of the Trial 
Written informed consent will be obtained for this study by the principal investigator or sub-
investigator from all subjects before the performance of any protocol-specific procedure (if the 
subject is less than 18 years of age, written consent will be obtained from their guardian or 
legally authorized representative, with verbal assent from the child).  
Please see Section 6.1 for detailed schedule, and Section 7 for listings of all tests required in each 
panel.  
6.3. 
Screening Period (Days –28 to –1) 
The following procedures will be performed within 28 days prior to enrollment: 
All screening laboratory tests will be analyzed at the Central Lab, with the exception of 
urinalysis and pregnancy test, which will be done in-house at the participating institution’s 
laboratory using the testing materials provided by the Central Lab.  The results of all screening 
laboratory tests should be reviewed prior to enrollment.  If these results confirm an exclusion 
criterion or suggest any contraindication to treatment with ALN-PCSSC, and/or other required 
ancillary medication(s), the subject must not be enrolled. 
1. Review of inclusion/exclusion criteria to confirm subject eligibility.
2. Documentation of:
a.
Demography: age, gender and ethnic origin
b. Medical history
c.
Concomitant medications
3. Full physical examination including height, weight and full neurological examination (as
described in Appendix A).
4. Vital signs (blood pressure and heart rate).
5. Blood samples drawn for screening clinical laboratory tests and results reviewed prior to
enrollment.  All laboratory testing will be performed with subjects in a fasted state.
a.
Biochemistry
b. Inflammatory markers
c.
Lipids/lipoproteins
d. Hematology
e.
Coagulation
f.
HbA1c
g. Biomarker (stored samples)
h. Pharmacogenetics (stored samples, only if separate consent has been signed)
6. Urinalysis (local), using standardized supplies from Central Lab.
7. Urine pregnancy test (local), using standardized supplies from Central Lab, for females of
childbearing potential. In addition, postmenopausal women who are less than 55 years of
age must have a negative pregnancy test within 24 hours of enrollment.


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
37 
6.4. 
Enrollment (Day 1) 
Enrollment should only occur once subject eligibility is confirmed.  
The following procedures will be performed prior to the injection of study drug: 
1. Review of inclusion/exclusion criteria
2. Vital signs (blood pressure and heart rate will be measured prior to injection and at 4
hours after injection)
3. 12-lead ECG
4. Blood samples drawn for clinical laboratory tests (Central Lab):
a.
Biochemistry
b. Inflammatory markers
c.
Lipids/lipoproteins
d. Hematology
e.
Coagulation
f.
HbA1c
g. Anti-ALN-PCSSC (ADA) antibodies (prior to and 4 hours after the injection)
h. Biomarkers (stored samples)
5. Urinalysis (local)
6. Urine pregnancy test (local), for females of childbearing potential. In addition,
postmenopausal women less than 55 years of age will have a pregnancy test within 24
hours of enrollment.  Results must be available prior to the first injection of study drug
7. Concomitant medications
8. AE reporting
9. SAE reporting
10. Enrollment (only after subject eligibility is confirmed)
If eligible, the subject will receive the first injection (SC) of study drug and will be observed in 
the clinic for at least 4 hours post-injection before being discharged. The site of injection is the 
abdomen. The injection site will be marked and mapped for later observation 
The following procedures will be performed 4 hours after the injection: 
11. Vital signs: blood pressure and heart rate
12. Blood samples drawn for Anti-ALN-PCSSC (ADA) antibodies
13. Concomitant medications
14. AE reporting
15. SAE reporting


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
38 
6.5. 
Follow-up Visits FU 1-6 
Subjects will return to the study center after study drug administration for Follow-Up Visits 
according to the Schedule of Events/Assessments (Section 6.1) until the end of the study.  
Procedures will be as follows: 
1. Vital signs (blood pressure and heart rate will be measured prior to injection and at 4
hours after injection)
2. Blood samples drawn for clinical laboratory tests:
a.
Biochemistry
b. Inflammatory markers
c.
Lipids/lipoproteins
d. Hematology
e.
Coagulation
f.
HbA1c (only at Days 90 and 180 and Day 270 if applicable)
g. Anti-ALN-PCSSC (ADA) antibodies (only at Day 30 and Day 150)
h. Biomarkers (stored samples)
3. Urine pregnancy test (local) for females of childbearing potential.  In addition, on Day 90
or 104 (if a second dose of study drug is required), postmenopausal women less than 55
years of age will have a pregnancy test and results must be available prior to the injection
4. Concomitant medications
5. AE reporting
6. SAE reporting
7. Study drug administration ONLY for subjects requiring a second dose of study drug
(depending on the degree of suppression of serum PCSK9 as compared to baseline).
If a second dose is deemed necessary, the subject will receive the injection (SC) at Day
90 or 104, based on the PCSK9 levels from the previous visit. The site of injection is the
abdomen (on the opposite side than the injection on Day 1).  The injection site will be
marked and mapped for later observation
6.6. 
End of Study (EOS) Visit (FU 7) 
A subject’s participation in the study is complete when all procedures at the last study visit have 
been completed and all ongoing SAEs have been followed to resolution (refer to Section 8.1.1). 
Procedures will be as follows: 
1. Vital signs (blood pressure and heart rate)
2. Physical examination (including full neurological examination as described in
Appendix A)
3. 12-lead ECG
4. Blood samples drawn for clinical laboratory tests:
a.
Biochemistry
b. Inflammatory markers


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
39 
c.
Lipids/lipoproteins
d. Hematology
e.
Coagulation
f.
Anti-ALN-PCSSC (ADA) antibodies
g. Biomarkers (stored samples)
5. Urinalysis (local)
6. Urine pregnancy test (local) for females of childbearing potential
7. Concomitant medications
8. AE reporting
9. SAE reporting
6.7. 
Additional Follow-Up Visits (FU 8-11, if needed) 
These visits are only for those subjects in whom LDL-C reduction is less than 20% of the 
absolute reduction from baseline to Day 90. Procedures will be as follows: 
1. Blood samples drawn for clinical laboratory tests:
a.
Biochemistry
b. Inflammatory markers
c.
Lipids/lipoproteins
d. Hematology
e.
Coagulation
f.
HbA1c (only at Day 270)
g. Anti-ALN-PCSSC (ADA) antibodies (only at last visit)
h. Biomarkers (stored samples)
2. Urinalysis (local)
3. Urine pregnancy test (local). Females of childbearing potential will have a pregnancy test
at each additional follow-up visit until LDL-C reduction is less than 20% of the absolute
reduction from baseline to Day 90
4. Concomitant medications
5. AE reporting
6. SAE reporting


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
40 
7. 
PROTOCOL ASSESSMENTS 
7.1. 
Assessment of Safety 
7.1.1. 
Adverse Events 
Subjects will be carefully monitored for adverse events by the investigator during the designated 
study period (see Section 6.1 for details).   
7.1.2. 
Demographics and Medical History 
Baseline demographic information will be collected during screening, and will include age, sex 
and race/ethnicity. 
Relevant medical history includes all ongoing medical or surgical issues. Remote medical and 
surgical history > 5 years from the time of screening should only be included if considered 
relevant to the study. 
7.1.3. 
Vital Signs 
Vital signs will include heart rate and blood pressure. 
7.1.4. 
Electrocardiograms 
12-Lead ECGs will be collected at Day 1 and at the EOS visit only, unless clinically indicated. 
7.1.5. 
Physical Examination 
The physical examination should include a focused examination, which may include general, 
respiratory, cardiovascular, abdominal, extremities, and recording of height, weight. 
The physical examination should also include a full neurologic evaluation as described in 
Appendix A. 
7.1.6. 
Clinical Laboratory Assessments 
Specimens will be obtained at the time points in the Schedule of Assessments (Section 6.1). Additional 
aliquots of plasma or serum will be collected at each time point and stored for any clinically indicated 
efficacy or safety analyses to be conducted at the end of the study.  
Subjects will be in a fasted state for all clinical laboratory assessments. Screening lab tests will be 
performed by the Central Lab, with the exception of urinalysis and pregnancy test, which will be done 
in-house at the participating institution’s laboratory using testing materials supplied by the Central 
Lab. Results from these screening tests must be available before the start of study drug injection on 
Day 1 to confirm subjects meet eligibility criteria. Details regarding the processing, shipping, and 
analysis of samples will be provided in the Laboratory Manual. Note: Efficacy laboratory assessments 
(e.g., LDL-C and PCSK9) are described in Section 7.2. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
41 
Laboratory assessments will include: 
Biochemistry: AST, ALT, alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), 
uric acid, total bilirubin (TBIL), direct bilirubin, indirect bilirubin, lactate, bicarbonate, sodium, 
creatine kinase (CK), albumin, total protein urea (BUN), creatinine, potassium, chloride, glucose 
(fasting), inorganic phosphate, eGFR, calcium, and tryptase (as required). 
Inflammatory markers: hsCRP (fasting), IL6, IFN-γ, and TNF-α 
Hematology: hemoglobin, hematocrit, erythrocytes, reticulocytes, platelet counts, mean cell 
hemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration 
(MCHC), white blood cell count, differential blood count. 
Coagulation: prothrombin time (PT), international normalized ratio (INR), activated partial 
thromboplastin (aPTT). 
HbA1c: hemoglobin A1c 
Urinalysis: Urinalysis will be performed at the time points defined in the Schedule of Assessments 
and evaluated by dipstick analyses at the investigational site local lab (a standardized dipstick test will 
be supplied by the Central Lab). Urinalysis will be performed from a sample of mid-stream urine. In 
case of abnormal results, microscopy and other assessments will be performed at the local lab. The 
following parameters will be assessed: Nitrite, protein, glucose, ketone, urobilinogen, bilirubin, red 
blood cells (RBC)/erythrocytes, white blood count (WBC)/leukocytes, pH, urine sediment 
(microscopic examination will be performed in the event of abnormalities). 
Urine pregnancy: Urine pregnancy testing will be conducted locally at the visits specified in the 
Schedule of Assessments (a standardized pregnancy test will be supplied by the Central lab). 
7.1.7. 
Anti-ALN-PCSSC Antibodies 
Additional sample for analysis of the induction of antibodies will be collected at the time points 
in the Schedule of Assessments (Section 6.1).  
Aliquots of serum samples will be obtained and frozen, to permit future analysis of the effect of ALN-
PCSSC on the expression of these exploratory biomarkers. Biological samples for biomarker research 
will be retained on behalf of the Sponsor for one year following the last subject's last visit in the study. 
Details regarding the collection, processing, storage, and shipping will be in the Study Laboratory 
Manual.  
7.2. 
Assessment of Efficacy 
Specimens for assays of lipids/lipoproteins will be obtained at the time points in the Schedule of 
Assessments (Section 6.1). Subjects will be in a fasted state for all efficacy laboratory 
assessments. Parameters to be assessed will include: total cholesterol (TC), triglycerides, LDL-C, 
HDL-C, non-HDL-C, very low-density lipoprotein (VLDL-C), apolipoprotein A1 (Apo-A1), 
apolipoprotein B (Apo-B), lipoprotein(a) [Lp(a)], and PCSK9. 
7.2.1. 
Change in LDL-C 
The primary efficacy endpoint is the percentage change in LDL-C. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
42 
In addition, this study will assess absolute and percentage change in LDL-C as a secondary efficacy 
endpoint. 
Blood samples for determination of LDL-C (β-quantification) concentrations will be collected at the 
time points in the Schedule of Assessments. Details regarding the collection, processing, shipping, and 
storage of the samples will be provided in a Laboratory Manual.  
7.2.2. 
Change in Lipids/Lipoproteins 
Secondary efficacy assessments will include measurement of the effects of ALN-PCSSC on levels of 
lipids and lipoproteins including total cholesterol, triglycerides, LDL-C, HDL-C, non-HDL-C, VLDL-
C, Apo-A1, Apo-B, Lp(a), and PCSK9.  

Absolute change and percentage change in PCSK9 levels

Absolute change and percentage change in other lipids, and apolipoproteins

Biomarkers (stored samples): Additional aliquots of plasma and serum will be collected
at each time point and stored for additional analyses, including future analysis of
biomarkers of CV risk. These samples will be retained for 1 year following the last
subject's last visit in the study.
Plasma samples will be analyzed using a validated enzyme linked immunosorbent assay to determine 
PCSK9 protein concentration. Full details of the analytical methods used will be described in a 
separate bioanalytical report.  
7.3. 
Assessment of Pharmacogenetics 
A blood sample will be collected, preferably during screening, only from subjects who sign a 
separate consent for pharmacogenetics. Samples will be processed as described in the Laboratory 
Manual and stored. Genetic assessment will be performed by an accredited laboratory. This 
assessment will determine if there is a different response for LDL-C lowering based on the type 
of mutation(s). 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
43 
8. 
ADVERSE EVENTS 
8.1. 
Definitions 
8.1.1. 
Adverse Event 
Adverse Event (AE): Any untoward medical occurrence in a patient or clinical trial subject 
administered a medicinal product and which does not necessarily have a causal relationship with 
this treatment. An adverse event can therefore be any unfavorable and unintended sign (eg, an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal product.  
Planned hospital admissions and/or surgical operations for an illness or disease that existed 
before the study drug was given or the subject was randomized in a clinical study are not to be 
considered AEs. 
Adverse events or abnormal test findings will be followed until the event (or its sequelae) or the 
abnormal test finding resolves or stabilizes at a level acceptable to the Sponsor/Investigator. 
8.1.2. 
Serious Adverse Event 
A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 

Results in death,

Is life-threatening, i.e., the subject was, in the opinion of the investigator, at
immediate risk of death from the event as it occurred (it does not include an event
that, had it occurred in a more severe form, might have caused death),

Results in a significant, persistent or permanent change, impairment, damage or
disruption in the subject's body function/structure, physical activities and/or quality of
life,

Requires in-subject hospitalization or prolongs hospitalization,

Is a congenital anomaly/birth defect, or

Is another medically significant event where medical and scientific judgement should
be exercised in deciding whether other situations should be considered serious
reactions, such as important medical events that might not be immediately life
threatening or result in death or hospitalization but might jeopardize the subject or
might require intervention to prevent one of the other outcomes listed above.
Examples of such events are intensive treatment in an emergency room or at home for
allergic bronchospasm, blood dyscrasias or convulsions that do not result in
hospitalization or development of dependency or abuse. Any suspected transmission
via a medicinal product of an infectious agent is also considered a serious adverse
reaction.


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
44 
8.1.3. 
Medication Errors 
Medication error refers to any unintended error in the dosing and/or administration of the study 
drug as per instructions in the protocol.  Medication errors generally fall into 4 categories as 
follows: 

wrong study drug;

wrong dose (including dosing regimen, strength, form, concentration, amount,
including above the maximum or under the minimum recommended dose);

wrong route of administration;

wrong subject (i.e. not administered to the intended subject)
8.2. 
EVALUATING ADVERSE EVENTS 
8.2.1. 
AE Severity 
The severity of an AE will be assessed by the investigator.  The investigator should ensure that 
any subject experiencing an AE receives appropriate medical support until the event resolves. 
Adverse events (AE) will be graded on a 3-point scale and reported as indicated on the case 
report form.  The intensity of an AE is defined as follows: 
1 = Mild: Discomfort noticed, but no disruption to daily activity. 
2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity. 
3 = Severe: Inability to work or perform normal daily activity. 
A distinction should be drawn between serious and severe AEs. Severity is an estimate or 
measure of the intensity of an AE, while the criteria for serious AEs are indications of adverse 
subject outcomes for regulatory reporting purposes. A severe AE need not necessarily be 
considered serious and a serious AE need not be considered severe. For example, nausea that 
persists for several hours may be considered severe nausea, but not an SAE. On the other hand, a 
myocardial infarction (MI) that may be considered minor could also be an SAE if it prolonged 
hospitalization. 
8.2.2. 
Study Drug Causality  
The relationship of an AE to study treatment (i.e. ALN-PCSSC) will be assessed with 
consideration to the following criteria: 

Temporal relationship to the initiation of study medication

Response of the event to withdrawal of study medication

AE profile of concomitant therapies

Clinical circumstances during which the AE occurred

Subject’s clinical condition and medical history


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
Protocol Amendment 1
The Medicines Company 
Confidential 
45 
Categorization of causality will be designated by the investigator as stated below: 
Reasonable possibility - There are facts (evidence) or arguments to suggest a causal relationship 
between the event and the study drug.  
No Reasonable possibility - There are few to no facts (evidence) or arguments to suggest a 
causal relationship between the event and the study drug. 
8.2.3. 
Adverse Event of Special Interest (AESIs) 
An adverse event of special interest (serious or nonserious) is one of scientific and medical 
concern specific to the Sponsor’s study drug or program, which warrants ongoing monitoring 
and rapid communication by the investigator to the sponsor. Such an event might warrant further 
investigation in order to characterize and understand it. 
The following AESI(s) have been identified for the study drug ALN-PCSSC in this protocol. 

Injection site reactions (ISR)
Injection site reactions including individual signs or symptoms at the injection site reported 
following study drug administration will be collected as an AESI. 
The grade (severity) of injection site reaction will be determined by the Common Terminology 
Criteria for Adverse Events (CTCAE) criteria of Injection Site Reaction (General disorders and 
administration site conditions) (see Table 2). 
Table 2: 
Common Terminology Criteria for Adverse Events (CTCAE) of Injection 
Site Reaction 
Grade I: Tenderness with or without associated symptoms (eg, warmth, erythema, itching) 
Grade II: Pain; lipodystrophy; edema; phlebitis 
Grade III Ulceration or necrosis; severe tissue damage; operative intervention indicated 
Grade IV Life-threatening consequences; urgent intervention indicated 
Grade V Death 
Reference: Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03, Published 14 June 2010. 
As indicated in Section 5.3 and Section 8.2.3, photographs of ISR should be obtained either by 
the investigator or another health care professional at first presentation and at each of the follow-
up visits until the injection site reaction resolves, if possible.  
Potential anaphylactic reactions will be assessed using the Sampson Criteria (Appendix B). 
8.2.4. 
Special Situations 
Collection, evaluation, and/or reporting of safety information is required by the regulatory 
authorities in special situations.  


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
46 
The special situations not previously defined include the following: 

Suspected transmission via a medicinal product of an infectious agent

Drug interactions

Occupational exposure
8.3. 
PROCEDURE FOR ADVERSE EVENT REPORTING 
8.3.1. 
Procedure for Non-Serious Adverse Event Recording 
All non-serious AEs that occur during the designated study period from enrollment up to EOS 
must be assessed and recorded on the source documents and eCRF, regardless of causal 
relationship to the study drug.   
8.3.2. 
Procedure for Serious Adverse Event Reporting 
All SAEs that occur during the designated study period from enrollment up to EOS must be 
reported to the Sponsor’s Global Pharmacovigilance Department (GPV) within 24 hours of 
awareness of the event using the provided study specific SAE/AESI Report Form.  In addition to 
completing the SAE/AESI Report Form, each SAE/AESI must be entered on the appropriate 
page of the case report form (CRF).   
The investigator must assess the causality for each SAE/AESI. 
The Sponsor will contact the investigator, if necessary, to clarify any of the event information. 
The investigator should provide any follow-up information for the event to the Sponsor on an 
updated SAE/AESI report form as soon as it becomes available. 
If the investigator is notified of a SAE/AESI that occurs post-study period, that he or she wishes 
to report to the Sponsor (e.g., an event suspected to be causally related to study drug), the event 
should be reported through the process described above.  
Where appropriate, if required by local regulations or procedures, the investigator should report 
these events to the Institutional Review Board (IRB)/Ethics Committee (EC) and/or national 
regulatory authority in addition to the Sponsor. 
8.3.3. 
Procedure for Medication Error Reporting For Study Drug 
Medication errors with or without an associated AE need to be recorded as medication errors in 
the eCRF as described in Section 8.1.3. 
Medication errors with an associated SAE need to be recorded as medication errors in the eCRF 
and reported to the Sponsor’s Global Pharmacovigilance Department as described in 
Section 8.3.2. 
8.3.4. 
Procedure For Reporting Adverse Events Of Special Interest (AESIs) 
Injection Site Reaction has been identified as an AESI for the study product(s) in this protocol as 
per Section 8.2.3. The SAE/AESI form should be utilized for reporting the AESI even if a 
serious outcome may not apply, and the form should indicate that the reported event is an AESI. 
Non-serious AESIs should be reported to the Sponsor within 72 hours and serious AESIs should 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
47 
be reported to the Sponsor within 24 hours. In both instances, the reporting procedure provided 
in Section 8.3.2 should be followed.  
8.3.5. 
Procedure For Reporting Pregnancies Exposure 
Occurrences of pregnancy in a study subject or study subject’s partner should be reported within 
24 hours using the Pregnancy Reporting Form. In cases where a pregnancy occurs with a Serious 
Adverse Event, the Serious Adverse Event reporting form should be used to report the 
SAE/AESI and the Pregnancy Reporting form should be used to report the pregnancy. When a 
pregnancy occurs without any concurrent SAE, the Pregnancy Reporting Form may be submitted 
alone.  The pregnancy must be followed through to outcome of pregnancy.  Any pregnancy 
discovered from the time of consent to follow-up needs to be reported. 
8.3.6. 
Procedure For Reporting Special Situations 
The occurrence of a Special Situation event, defined in Section 8.2.4, must be reported to the 
Sponsor as per Section 8.3.2, Procedure for Serious Adverse Event Reporting. Note: The Special 
Situations event does not need to be serious to be reported on the SAE/AESI Report form. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
48 
9. 
DATA COLLECTION 
An electronic data capture (EDC) system which is 21 CFR Part 11 compliant will be used for 
this trial.  All users will be trained on the technical features of the EDC as well as the content of 
the eCRF by qualified personnel prior to gaining access to the EDC.  A UserID/Password will be 
granted after training.  This ID is not to be shared amongst the study staff.  All users must have a 
unique account to enter or review data.  The eCRF should be filled out by the site 3 days after 
each visit.  It is not expected that the eCRF will serve as source for any data collected in this 
trial.  If there is a reason for a site to do so, it must be approved by Sponsor and documented in 
the site files. 
Prior to the database being locked, the investigator or designee will review, approve and 
sign/date each completed eCRF.  This signature serves as attestation of the Investigator’s 
responsibility for ensuring that all data entered into the eCRF are complete, accurate and 
authentic.  After the end of the trial, a copy of the data will be provided to the site.  This copy 
will contain the final data, an audit trail of activity on the data, and any queries and answers that 
were posted for data clarification. 
For this study, the End of Trial will be defined as the last visit of the last subject. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
49 
10.
STATISTICAL PLAN
This is an 8-10 subject non-randomized pilot study. Subjects with homozygous familial 
hypercholesterolemia will be recruited from approximately 5 sites globally.  Subjects that qualify 
for entry into the study will be enrolled to receive ALN-PCSSC.  The primary objective of this 
study is to characterize the effect of 90 and 180 days of subcutaneous ALN-PCSSC on the percent 
change from Day 1 in low-density lipoprotein cholesterol (LDL-C) in subjects with homozygous 
familial hypercholesterolemia.  A separate Statistical Analysis Plan (SAP) document will provide 
more detailed specifications in data analysis and presentation. 
The primary hypothesis is that ALN-PCSSC, when used in combination with maximally tolerated 
statin therapy with or without ezetimibe, will be well-tolerated, will suppress circulating PCSK9 
>70% and will result in reduction of LDL-C, defined as mean percent change from Day 1 
following 90 and 180 days of treatment, in subjects with homozygous familial 
hypercholesterolemia.  
10.1. 
Sample Size  
The sample size was chosen based on clinical considerations. 
10.2. 
Randomization 
This study is non-randomized. 
10.3. 
General Statistical Considerations and Definitions 
10.3.1. 
General Statistical Methods 
All study-collected data will be summarized by treatment group using descriptive statistics, 
graphs, and/or raw data listings. Descriptive statistics for continuous variables will include 
number of subjects (n), mean, standard deviation (SD), median, quartiles (Q1 and Q3), minimum 
(min) and maximum (max) values. Analysis of categorical variables will include frequency and 
percentage. 
Summary statistics for continuous variables will include the number of subjects, mean, median, 
standard deviation or standard error, minimum and maximum. For categorical variables, the 
frequency and percentage will be given.  
10.3.2. 
Analysis Populations 
The following populations will be used for data analyses and/or presentation. 
10.3.2.1. Modified Intent-to-Treat (mITT) Population 
All ITT subjects (who receive at least one dose of study drug), who have baseline and at least 
one post-baseline measurement for the primary endpoint.  This will be the primary population for 
the efficacy analyses; unless specified otherwise, the mITT will be the default analysis set in this 
study. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
50 
10.3.2.2. Safety Population 
All subjects who received at least one dose of study drug. Treatment classification will be based 
on the actual treatment received. This will be the primary population for the safety analyses. 
The primary analysis set is the modified Intent-to-Treat (mITT), which will include all enrolled 
subjects who have received at least one dose of study drug. Unless specified otherwise, the mITT 
will be the default analysis set in this study. 
10.3.3. 
Analysis Windows and Baseline 
The observational period for the study includes the screening period (Day -28 to Day -1), 
treatment and follow up period (Day 1 to Day 180), additional follow up period (up to Day 300, 
only for subjects in whom LDL-C reduction is less than 20% of the absolute reduction from 
baseline to Day 90). Any event occurring beyond the defined observational period, even if 
collected on the CRF, will not be included in the planned statistical analysis.  However, all data, 
including that reported after the defined observational period, will be included in the subject data 
listings.   
Unless otherwise specified, for evaluations that are collected at multiple occasions prior to 
initiation of study drug administration, the latest evaluation will be considered the "Baseline" 
evaluation for analysis. 
10.3.4. 
Missing Data Handling 
Missing data will not be imputed. 
10.4. 
Statistical Analyses 
10.4.1. 
Demographic and Background Characteristics 
Subject demographics and baseline characteristics will be summarized by treatment group using 
the mITT and safety populations. 
10.4.2. 
Study Drug and Concomitant Medications 
Summary of each prior (pre-Day 1) medication and concomitant (Day 1 or later) medication will 
be provided by treatment.  [Medication will be coded with WHO drug dictionary]. Subjects will 
be counted only once within each period by medication. 
10.4.3. 
Efficacy Analysis 
10.4.3.1. Primary Efficacy Endpoint 
The primary endpoint is the percent change in LDL-C following 90 and 180 days of treatment. 
Summary statistics and 95% CI of this primary endpoint will be provided. Changes of LDL-C 
from Day 1 by scheduled visits will also be summarized. Response rate of subjects with 15% or 
greater reduction in LDL-C from Day 1 following 90 and 180 days of treatment will be 
calculated. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
51 
The analysis for the primary endpoint will be descriptive. Means and confidence intervals will be 
provided. 
10.4.3.2. Secondary Efficacy Endpoints  
Analyses of secondary efficacy endpoints will be similar to the primary analysis of the primary 
endpoint.  
10.4.3.3. Tertiary Efficacy Endpoints  
Formation of Anti-drug antibodies (ADA) to ALN-PCSSC 
Response of LDL-C by the causal genetic mutations of HoFH 
10.4.4. 
Safety Analysis 
Safety summaries will include the incidence of adverse events, summaries of laboratory 
parameters (including shift tables), vital signs, ECGs and anti-drug antibodies. 
10.4.4.1. Adverse Events 
The Medical Dictionary for Regulatory Activities (MedDRA) will be used for coding adverse 
events (AEs).  An AE (classified by preferred term) occurring during the study drug treatment 
period will be counted as a treatment emergent AE (TEAE) either if it is not present at baseline 
or if it is present at baseline but increased in severity during the treatment period. 
The number (percentage) of subjects reporting TEAEs for each preferred term will be tabulated 
by system-organ class, by system-organ class and severity, and by system-organ class and 
relationship to study drug.  If more than one event occurred with the same preferred term for the 
same subject, the subject will be counted only once for that preferred term using the most severe 
or related occurrence for the summary by severity, or relationship to study drug, respectively. 
10.4.4.2. Laboratory Tests 
Laboratory values will be summarized by treatment group, including changes and percent 
changes from Day 1 at each time point. Analyses will also be performed for each lab parameter 
by treatment group for incidence rates of potentially clinical significant (PCS) values for subjects 
without PCS value at baseline. 
10.4.4.3. Vital Signs  
Change and percent change from baseline in vital signs will be summarized descriptively at each 
scheduled time point by treatment group. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
52 
11.
RECORDS RETENTION
FDA regulations require all investigators participating in clinical study drug/device trials to 
maintain detailed clinical data for one of the following periods: 

At least two years following the date on which a New Drug Application is approved
by the FDA, or

Two years after the Sponsor notifies the investigator that no further application is to
be filed with the FDA.
Similarly, current EU Directives / Regulations and ICH guidelines collectively require that 
essential clinical trial documents (including case report forms) other than subject’s medical files 
must be retained for the following time period: 

— for at least 15 years after completion or discontinuation of the trial,

— or for at least two years after the granting of the last marketing authorisation in the
European Community and when there are no pending or contemplated marketing
applications in the European Community,

— or for at least two years after formal discontinuation of clinical development of the
study drug/device.
Subject's medical files should be retained in accordance with applicable legislation and in 
accordance with the maximum period of time permitted by the hospital, institution or private 
practice.  The documents can be retained for a longer period, however, if required by the 
applicable regulatory requirements or by agreement with the sponsor.  
To comply with these requirements, the investigator will not dispose of any records relevant to 
this study without either (1) written permission from the Sponsor or (2) providing an opportunity 
for the Sponsor to collect such records.  The investigator shall take responsibility for maintaining 
adequate and accurate hard copy source documents of all observations and data generated during 
this study, including the hard copy or discs received from the sponsor of the final data.  Such 
documentation is subject to inspection by the Sponsor or its agents, the FDA and/or other 
regulatory agencies. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
53 
12.
QUALITY CONTROL AND QUALITY ASSURANCE
12.1. 
Monitoring 
The Sponsor has ethical, legal and scientific obligations to carefully follow this study in 
accordance with established research principles and applicable regulations.  The investigator, as 
part of his responsibilities, is expected to cooperate with the Sponsor in ensuring that the study 
adheres to the protocol and GCP requirements.   
As part of a concerted effort to fulfill these obligations, the Sponsor's monitor will visit the 
center(s) during the study in accordance with the Monitoring Plan set forth for this trial.  The 
investigator will permit the Sponsor to monitor the study as frequently as is deemed necessary 
and provide access to medical records/source documents to ensure that data are being recorded 
adequately, that data are verifiable and that protocol adherence is satisfactory.   
12.2. 
Auditing 
The Sponsor may conduct audits at the study center(s).  Audits will include, but not be limited to, 
study drug supply, presence of required documents, the informed consent process, and 
comparison of eCRFs with source documents.  The investigator agrees to permit audits 
conducted at a reasonable time in a reasonable manner. 
Regulatory authorities worldwide may also inspect the investigator during or after the study.  
The investigator should contact the Sponsor immediately if this occurs, and must permit 
regulatory authority inspections. 
12.3. 
Protocol Deviations 
This study will be conducted as described in this protocol, except for an emergency situation in 
which the protection, safety, and well-being of the subject requires immediate intervention, 
based on the judgment of the investigator (or a responsible, appropriately trained professional 
designated by the investigator). In the event of a significant deviation from the protocol due to an 
emergency, accident, or mistake, the investigator or designee must contact the Sponsor, or their 
agent, at the earliest possible time by telephone. This will allow an early joint decision regarding 
the subject’s continuation in the study. The investigator and the Sponsor will document this 
decision. The IRB/EC will be informed of all protocol changes by the investigator in accordance 
with the IRB/EC established procedure. No deviations from the protocol of any type will be 
made without complying with all the IRB/EC established procedures. 
The following Protocol Deviations will require additional information in the eCRF explaining 
why the deviation occurred and what will be done to prevent it from re-occurring: 

Inclusion criteria violation

Exclusion criteria violation

Injection not administered for any reason other than subject safety or withdrawal


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
54 

Wrong dose (dose concentration, wrong dose, wrong treatment, wrong regimen,
wrong injection site)*

Missed assessment as per the Schedule of Events/Assessments (Section 6.1) at
Baseline, dosing visits and EOS

Subject not adhering to protocol subject restrictions

Subject taking any prohibited concomitant medication
*If the mis-dosing was unintended, i.e. a medication error, the error should be reported as per
instructions in Section 8.3.3, Procedure for Medication Error Reporting. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
55 
13.
ETHICS AND RESPONSIBILITY
This study will be conducted in compliance with the protocol, the Sponsor’s standard operating 
procedures and/or guidelines, the United States Food and Drug Administration (FDA) 
regulations, the International Conference on Harmonization (ICH) GCP guidelines, the 
Declaration of Helsinki and other local regulations, as applicable. 
13.1. 
Informed Consent 
Written informed consent will be obtained from all subjects (or their guardian or legally 
authorized representative), and whenever possible, verbal assent will be obtained from children 
12 years of age or older, or as per IRB guidelines, before any study-related procedures (including 
any pre-treatment procedures) are performed.  The investigator(s) has both ethical and legal 
responsibility to ensure that each subject (and their guardian or legally authorized representative) 
being considered for inclusion in this study is given a full explanation of the protocol.  This shall 
be documented on a written informed consent form, which shall be approved by the same IRB or 
EC responsible for approval of this protocol.  Each informed consent form shall include the 
elements required by ICH, Part E6, Section 4.8 and any applicable local regulations.  The 
investigator agrees to obtain approval from the Sponsor of any written informed consent form 
used in the study, preferably prior to submission to the IRB or EC.  
Once the appropriate essential information has been provided to the subject and fully explained 
by the investigators (or a qualified designee) and it is felt that the subject understands the 
implications of participating, the subject and the investigator (or designee) shall sign the IRB- or 
EC-approved written informed consent form.  The subject shall be given a copy of the signed 
informed consent form, and the original shall be filed appropriately, according to the institution.  
A second copy may be filed in the subject's medical record, if allowed by the institution. 
13.2. 
Institutional Review Board/Ethics Committee 
This protocol, the written informed consent form and any materials presented to subjects shall be 
submitted to the IRB or EC identified with this responsibility.  Notification in writing of 
approval must come from the IRB or EC chairman or secretary, to the investigator, either as a 
letter or as a copy of the appropriate section of the IRB or EC meeting minutes where this 
protocol and associated informed consent form were discussed.  The investigator will not 
participate in the decision.  If the investigator is an IRB or EC member, the written approval 
must indicate such non-participation in the voting session.  The investigator will submit status 
reports to the IRB or EC as required by the governing body.  The IRB or EC must be notified by 
the investigator in writing of the interruption and/or completion of the study; the investigator 
must promptly report to the IRB or EC all changes in research (protocol amendments) and will 
not make such changes without IRB or EC approval, except where necessary to eliminate 
apparent immediate hazards to human subjects.  In cases where it is necessary to eliminate 
immediate hazards to subjects, the IRB or EC must then be notified of the change as per local 
requirements.  The investigator is required to maintain an accurate and complete record of all 
written correspondence to and received from the IRB or EC and must agree to share all such 
documents and reports with the Sponsor.  


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
56 
14.
CONFIDENTIALITY
All information generated in this study must be considered highly confidential and must not be 
disclosed to any persons not directly concerned with the study without written prior permission 
from the Sponsor.  However, authorized regulatory officials and Sponsor personnel will be 
allowed full access to the records.  All medications provided and subject bodily fluids and/or 
other materials collected shall be used solely in accordance with this protocol, unless otherwise 
agreed to in writing by the Sponsor. 
Only unique subject numbers in eCRFs will identify subjects.  Their full names may, however, 
be made known to a product regulatory agency or other authorized official if necessary. 
With respect to the clinical trial data that is received from countries in the European Economic 
Area and Switzerland, MDCO has certified adherence to the US-EU and the US-Swiss Safe 
Harbor Principles.  


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
Protocol Amendment 1 
The Medicines Company 
Confidential 
57 
15.
INVESTIGATOR AGREEMENT
I have read and understand the protocol (including the Investigator’s Brochure) and agree that it 
contains all the ethical, legal and scientific information necessary to conduct this study.  I will 
personally conduct the study as described. 
I will provide copies of the protocol to all physicians, nurses and other professional personnel 
responsible to me who will participate in the study. I will discuss the protocol with them to 
assure myself that they are sufficiently informed regarding the new study drug ALN-PCSSC, the 
concurrent medications, the efficacy and safety parameters and the conduct of the study in 
general. I am aware that this protocol must be approved by the Institutional Review Board (IRB) 
or Ethics Committee (EC) responsible for such matters in the Clinical Study Facility where 
ALN-PCSSC will be tested prior to commencement of this study. I agree to adhere strictly to the 
attached protocol.  I understand that this IRB or EC approved protocol will be submitted to 
relevant regulatory authorities by the Sponsor, as appropriate. I agree that clinical data entered on 
case report forms by me and my staff will be utilized by the Sponsor in various ways such as for 
submission to governmental regulatory authorities and/or in combination with clinical data 
gathered from other research sites, whenever applicable. I agree to allow Sponsor monitors and 
auditors full access to all medical records/source documents at the research facility for subjects 
screened or enrolled in the study. 
I agree to provide all subjects with informed consent forms, as required by government and ICH 
regulations. I further agree to report to the Sponsor any adverse experiences in accordance with 
the terms of this protocol, ICH guideline, Part E6, Section 4.11 and applicable local regulations. 
Principal Investigator (Signature) 
Date 
Principal Investigator (Printed Name) 
Protocol Version: Amendment 1 
(07 November 2016) 
Institution Name 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
58 
16.
REFERENCES
ALN-TTRSC-001; EudraCT 2012-004203-12. 
ALN-TTRSC-002; EudraCT 2013-002856-33. 
Abifadel M, Varret M, Rabès JP, et al, Mutations in PCSK9 cause autosomal dominant 
hypercholesterolemia. Nat Genet. 2003;34(2):154-6. 
Ashwell G and Morell AG, The role of surface carbohydrates in the hepatic recognition and 
transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol. 1974;41(0):99-
128. 
Banerjee Y, Shah K, and Al-Rasadi K. Effect of a monoclonal antibody to PCSK9 on LDL 
cholesterol. N Engl J Med. 2012;366(25):2425-6; author reply: 2426. 
Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy 
and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 
170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81.  
Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin 
amyloidosis. N Engl J Med. 2013;369(9): 819-29. 
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low 
LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-72. 
Cuchel M, Bruckert E, Ginsberg HN et al. Homozygous familial hypercholesterolaemia: new 
insights and guidance for clinicians to improve detection and clinical management. A 
position paper fromthe Consensus Panel on Familial Hypercholesterolaemia of the European 
Atherosclerosis Society. European Heart Journal 2014; 35: 2146–2157. 
Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education 
(NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey 
and implications for treatment under the recent NCEP Writing Group recommendations. Am 
J Cardiol. 2005;96(4):556-63. 
Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density 
lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, 
ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on 
statins. J Am Coll Cardiol. 2012;60(19):1888-98. 
Elbashir SM, Garborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA 
interference in cultured mammalian cells. Nature. 2001;411(6836): 494-8. 
Foley KA, Simpson RJ Jr, Crouse JR 3rd, et al. Effectiveness of statin titration on low-density 
lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J 
Cardiol. 2003;92(1):79-81. 
Foody JM, Sajjan SG, Hu XH, et al. Loss of early gains in low-density lipoprotein 
cholesterol goal attainment among high-risk patients. J Clin Lipidol. 2010;4(2):126-32. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
59 
Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a 
lethal ebola virus challenge is conferred by RNA interference. J Infect Dis. 
2006;193(12):1650-7. 
Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the 
National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 
2004;110(2):227-39. 
Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is 
present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 
2007;193(2):445-8. 
Hooper AJ and Burnett JR. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. 
Expert opinion on biological therapy. 2013;13(3):429-35. 
Horton JD, Cohen JC, and Hobbs HH. PCSK9: a convertase that coordinates LDL 
catabolism. J Lipid Res. 2009;50 Suppl:S172-7. 
Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA 
mediating potent gene silencing in vivo. Mol Ther. 2006;13(3):494-505. 
Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 
18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 
2008;371(9607):117-25. 
Milazzo L and Antinori S. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. 
N Engl J Med. 2012;366(25):2425; author reply 2426. 
Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity 
of chemically modified siRNAs. Nat Biotechnol. 2005;23(8):1002-7. 
Mousavi SA, Berge KE, and Leren TP. The unique role of proprotein convertase 
subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med. 2009;266(6):507-19. 
Nag SS, Daniel GW, Bullano MF, et al. LDL-C goal attainment among patients newly 
diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care 
Pharm. 2007;13(8):652-663. 
Raal F, Scott R, Somaratne R, et al. Low-Density Lipoprotein Cholesterol-Lowering Effects 
of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 
Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The 
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial 
Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial. Circulation. 
2012;126(20):2408-17. 
Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of 
dyslipidaemias. The Task Force for the management of dyslipidaemias of the European 
Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). EHJ. 
2011;32:1769–1818. 
Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an Antibody to 
PCSK9 in Primary Hypercholesterolemia. N Engl J Med. 2012;367(20):1891-900. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
60 
Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and 
management of anaphylaxis: summary report. J Allergy Clin Immunol. 2005;115(3):584-91. 
Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition 
and management of anaphylaxis: summary report – Second National Institute of Allergy and 
Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin 
Immunol. 2006, 117(2):391-7. 
Soutschek J, Akinc A, Bramlage B, et al., Therapeutic silencing of an endogenous gene by 
systemic administration of modified siRNAs. Nature. 2004;432(7014): 173-8. 
Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on 
LDL cholesterol. N Engl J Med. 2012;366(12): 1108-18. 
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment 
of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the 
American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. Circulation. 2014;129(suppl 2):S1–S45. 
Sullivan D, Olsson AG, Scott R, et al. Effect of a Monoclonal Antibody to PCSK9 on Low-
Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS 
Randomized Trial. JAMA. 2012;308(23):2497-506. 
Tabernero J, Shapiro GI, LoRusso, et al. First-in-Humans Trial of an RNA Interference 
Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement. Cancer 
Discov. 2013;3(4):406-417. 
World Health Organization Cardiovascular Statistics, 2011, 
http://www.who.int/mediacentre/factsheets/fs317/en/index.html. 
Yusef S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated 
with myocardial infarction in 52 countries (the INTERHEART study): case-control study. 
Lancet. 2004;364:937-952. 
Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function 
mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 
2006;79(3):514-23. 
Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human 
primates. Nature. 2006;441(7089):111-4. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
61 
APPENDIX A. NEUROLOGICAL EXAMINATION 
MOTOR FUNCTION 
When assessing motor function, from a neurological perspective, the assessment should focus on 
arm and leg movement. You should consider the following: 
1. Muscle size
2. Muscle tone
3. Muscle strength
4. Involuntary movements
5. Posture, gait
Symmetry is the most important consideration when identifying focal findings. Compare one 
side of the body to the other when performing your assessment. 
Limb assessment of a conscious subject usually involves a grading of strength. 
Grade Strength 
Grade strength Description 
5 Full range of motion against gravity and resistance; normal muscle strength 
4 Full range of motion against gravity and a moderate amount of resistance; slight weakness 
3 Full range of motion against gravity only, moderate muscle weakness 
2 Full range of motion when gravity is eliminated, severe weakness 
1 A weak muscle contraction is palpated, but no movement is noted, very severe weakness 
0 Complete paralysis 
NB: In a conscious subject, the single best test to quickly identify motor weakness is the “drift 
test”. Have the subject hold their arms outward at 90 degrees from the body. With palms up, 
have the subject close their eyes and hold the arms for a couple of minutes. “Drifting” will occur 
if one side is weak. 
Lower Extremities 
Assess the subject in a supine position. Ask him/her to separate both legs to test for hip 
abduction. Then ask the subject to bring the legs back together to test for hip adduction. Sit the 
subject on the side of the bed to assess knee flexion and extension. Ask the subject to flex and 
extend the knee. If able to do this, apply resistance as these movements are repeated. Test plantar 
and dorsiflexion by having the subject push down against your hand with their foot and then pull 
up against your hand with their foot. Remember to compare the left side to the right side. 
Upper Extremities 
Assess ability to flex elbow (biceps) and straighten (triceps). Assess ability to raise shoulders and 
return to a resting position. Assess wrist flexion and extension. Test each function with 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
62 
resistance. For focused upper extremity assessment, assess each digit for flexion, extension and 
lateral movement. 
SENSORY FUNCTION 
When assessing sensory function remember that there are three main pathways for sensation and 
they should be compared bilaterally: 
1. Pain and temperature sensation
2. Position sense (proprioception)
3. Light touch
Pain can be assessed using a sterile pin. Light touch can be assessed with a cotton wisp. To test 
proprioception, grasp the subject's index finger from the middle joint and move it side to side and 
up and down. Have the subject identify the direction of movement. Repeat this using the great 
toe. 
Sensory Tests: 
A number of tests for lesions of the sensory cortex can be done. Examples include the following: 
Stereognosis: The ability to recognize an object by feel. Place a common object in the persons
hand and ask them to identify the object. 
Graphesthesis: “Draw” a number in the palm of the person’s hand and ask them to identify the
number. 
Two-Point Discrimination: Simultaneously apply two pin pricks to the skin surface.
Continually repeat the test while bringing the two pins closer together, until the individual can no 
longer identify two separate stimuli. The finger tips are the most sensitive location for 
recognizing two point differences while the upper arms, thighs and back are the least sensitive. 
Extinction: Touch the same spot on both sides of the body at the same time (eg, the left and
right forearms). Ask the individual to describe how many spots are being touched. Normally, 
both sides are felt; with sensory lesions the individual will sense only one. 
Point Locations: Touch the surface of the skin and remove the stimulus quickly. Ask the
individual to touch the spot where the sensation was felt. Sensory lesions can impair accurate 
identification, even if they retain their sensation of light touch. 
TONE and REFLEXES 
Upper motor neuron problems (brain and spinal cord) are associated with increased tone. Lower 
motor neuron problems are associated with decreased tone. 
Look at the muscles on each side of the body in pairs. Assess for symmetry of bulk. 
Evaluation of the stretch reflexes assesses the intactness of the spinal reflex arc at various spinal 
cord levels. The limb should be relaxed while applying a short and snappy blow with a reflex 
hammer. Hold the hammer loosely in a relaxed manner, making a wrist action. Allow the 
hammer to bounce. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
63 
Reflex responses: 
0 No response 
1+ Diminished, low normal 
2+ Average, normal 
3+ Brisker than normal 
4+ Very brisk, hyperactive 
Lower motor neuron disease is associated with 0 or 1+, upper motor neuron disease is associated 
with 3+ or 4+. 
Biceps Reflex (C5 – C6) 
Support the forearm on the examiners forearm. Place your thumb on the bicep tendon (located in 
the front of the bend of the elbow; midline to the anticubital fossa). Tap on your thumb to 
stimulate a response. 
Triceps Reflex (C7-C8) 
Have the individual bend their elbow while pointing their arm downward at 90 degrees. Support 
the upper arm so that the arm hangs loosely and “goes dead”. Tap on the triceps tendon located 
just above the elbow bend (funny bone). 
Brachioradialis Reflex (C5-C6): 
Hold the person’s thumb so that the forearm relaxes. Strike the forearm about 2-3 cm above the 
radial styloid process (located along the thumb side of the wrist, about 2-3 cm above the round 
bone at the bend of the wrist). Normally, the forearm with flex and supinate. 
Quadriceps Reflex (Knee jerk) L2 – L4 
Allow the lower legs to dangle freely. Place one hand on the quadriceps. Strike just below the 
knee cap. The lower leg normally will extend and the quadriceps will contract. 
If the subject is supine: Stand on one side of the bed. Place the examiners forearm under the 
thigh closest to the examiner, lifting the leg up. Reach under the thigh and place the hand on the 
thigh of the opposite leg, just above the knee cap. Tap the knee closest to the examiner, (the one 
that has been lifted up with the examiners forearm). 
Achilles Reflex (ankle jerks) L5 – S2: 
Flex the knee and externally rotate the hip. Dorsiflex the foot and strike the Achilles tendon of 
the heel. In conscious subjects, kneeling on a chair can help to relax the foot. 
Heel Lift 
While the subject is supine, bend the knee and support the leg under the thigh. Have the leg “go 
dead”. Briskly jerk the leg to lift the heel of the bed. Normally, the leg will remain relaxed and 
the heel will slide upward; increased tone will cause the heel and leg to stiffen and lift off the 
bed. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
64 
Babinski Response: 
Dorsiflexion of the great toe with fanning of remaining toes is a positive Babinski response. This 
indicates upper motor neuron disease. It is normal in infants. 
CEREBELLAR FUNCTION 
The cerebellum is responsible for muscle coordination and balance on the same side. To test 
cerebellar function use the following tests: 
1. Finger to finger test: have the subject touch their index finger to your index finger (repeat
several times). 
2. Finger to nose test: perform with eyes open and then eyes closed.
3. Tandem walking: heel to toe on a straight line.
4. Romberg test: stand with feet together and arms at their sides. Have subject close his/her eyes
and maintain this position for 10 seconds. If the subject begins to sway, have them open their 
eyes. If swaying continues, the test is “positive” or suggestive of cerebellum problems. 
Dizziness that occurs in response to position changes is usually blood pressure initiated. If the 
subject sways during a Romberg test, but stops when the eyes are opened, the problem is 
probably visual or CN VIII (vestibular). 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
65 
APPENDIX B. SAMPSON CRITERIA FOR DIAGNOSING 
ANAPHYLAXIS 
Anaphylaxis is highly likely when any one of the following three criteria is fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula) 
AND AT LEAST ONE OF THE FOLLOWING: 
a. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak
expiratory flow [PEF], hypoxemia) 
b. Reduced blood pressure or associated symptoms of end-organ dysfunction (eg, hypotonia
[collapse], syncope, incontinence) 
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that
subject (minutes to several hours): 
a. Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lips-
tongue-uvula) 
b. Respiratory compromise (eg, dyspnea, wheeze, bronchospasm, stridor, reduced PEF,
hypoxemia 
c. Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, incontinence)
d. Persistent gastrointestinal symptoms (eg, painful abdominal cramps, vomiting)
3. Reduced blood pressure after exposure to a known allergen for that subject (minutes to several
hours): 
a. Infants and children: low systolic blood pressure (age specific) or > 30% decrease in
systolic blood pressure* 
b. Adults: systolic blood pressure <90 mmHg or >30% decrease from that person’s baseline
*Low systolic blood pressure for children is age specific and defined as: <70 mmHg for age 1
month to 1 year; <70 mmHg + [2 x age] for age 1 to 10 years; <90 mmHg for age 11 to 17 years. 
Source: Sampson et al, 2005; Sampson et al, 2006. 


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
66 
APPENDIX C. TLC DIET 
Definition 
Although there are several diets that will result in lowered LDL cholesterol, the National 
Cholesterol Education Program (NCEP) set forth guidelines for medical professionals to follow 
when instructing patients on a medical nutrition option for lowering cholesterol. Termed the TLC 
diet or the Therapeutic Lifestyle Changes Diet it emphasizes heart healthy lifestyle choices. 
The Therapeutic Lifestyle Changes diet (TLC) is a cholesterol lowering diet that refers to a 
cholesterol-lowering treatment that lowers a person’s low-density lipoprotein (LDL) level and 
raises their high-density lipoprotein (HDL) level enough to reduce their risk of a heart attack or 
other chronic disease caused by hardening of the arteries. 
The TLC diet follows these dietary guidelines 

Less than 7% of the day’s total calories from saturated fat.

25-35% of the day’s total calories from fat.

Less than 200 milligrams of dietary cholesterol a day.
_________________________________________________________________________ 
TLC diet tips 
Meat, Poultry, Fish, Dry Beans, Eggs, and Nuts 

Limit the total amount of meat to 5 ounces or less per day

Choose chicken and turkey without skin or remove skin before eating

Eat fish, like cod, that has less saturated fat than either chicken or meat

Dry peas and beans and tofu (bean curd) are great meat substitutes

Limit egg yolks to no more than 2 yolks per week, including egg yolks in baked goods

Substitute egg whites for whole eggs
Milk, Yogurt, and Cheese 

Eat 2 to 3 servings per day of low-fat or nonfat dairy products

Choose varieties that have 3 grams of fat or less per ounce, including low-fat (1%) or
nonfat cottage cheese

Buy frozen desserts that are lower in saturated fat, like ice milk, low-fat frozen yogurt,
sorbet

Try low-fat or nonfat sour cream or cream cheese blends


ALN-PCSSC
Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1 
The Medicines Company 
Confidential 
67 
Fats and Oils 

Replace saturated fats with unsaturated fat and limit the total amount of fats or oils

Use liquid vegetable oils that are high in unsaturated fats (canola, corn, olive, peanut,
safflower, sesame, soybean, sunflower oils)

Use margarine made with unsaturated liquid vegetable oils as the first ingredient

Limit butter, lard, fatback, and solid shortenings

Buy light or nonfat mayonnaise and salad dressing
Fruits and Vegetables 

Eat at least 3 to 5 servings of fruits and vegetables each day

Buy fruits and vegetables to eat as snacks, desserts, salads, side dishes, and main dishes

Add a variety of vegetables to meat stews or casseroles or make a vegetarian main dish

Snack on raw vegetables (carrots, broccoli, cauliflower, lettuce)

Season with herbs, spices, lemon juice, vinegar, fat free or low-fat mayonnaise or salad
dressing
Breads, Cereals, Rice, Pasta, and Other Grains 

Eat 6 to 11 servings of foods from this group each day

Choose whole grain breads and rolls

Buy dry cereals, most are low in fat, and limit high fat granola, muesli, and oat bran types
made with coconut or coconut oil and nuts

Buy pasta and rice to use as entrees and eliminate the high fat sauces (butter, cheese,
cream)

Limit sweet baked goods that are made with lots of saturated fat
Sweets and Snacks 

Choose sweets and snacks only every now-and-then

Buy snack foods low in fat

Some sweets and snacks may be low in fat, but most are not low in calories

To reduce sodium intake, look for low sodium or unsalted varieties
____________________________________________________________________________ 

Limit sodium intake to 2400 milligrams or less per day.

Just enough calories to achieve or maintain a healthy weight and reduce your blood
cholesterol level.
Reference: http://www.diet.com/store/facts/tlc-diet 

SAP_001.pdf: 
Inclisiran 
ORION-2 (MDCO-PCS-16-02) 
The Medicines Company 
16.1.9 Statistical Analysis Plan 
Confidential 
1
STATISTICAL ANALYSIS PLAN 
Protocol No.: ORION-2 (MDCO-PCS-16-02) 
An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, 
Tolerability, and Efficacy of Inclisiran in Subjects with Homozygous Familial 
Hypercholesterolemia  
NCT02963311
14 November 2018


Inclisiran 
ORION-2 (MDCO-PCS-16-02) 
The Medicines Company 
16.1.9 Statistical Analysis Plan 
Confidential 
2
The Orion HoFH Study 
Protocol No.: ORION-2 (MDCO-PCS-16-02) 
An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, 
Tolerability, and Efficacy of inclisiran in Subjects with Homozygous Familial 
Hypercholesterolemia  
EuDRACT No.: 2016-003376-49 
PROTOCOL VERSION: Amendment 1.0, 7 Nov 2016 
SAP Version 2.0 14 November 2018 


Inclisiran 
 
ORION-2 (MDCO-PCS-16-02) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
3
 
 
 
  
 
TABLE OF CONTENTS 
1. 
TRIAL DESIGN ...........................................................................................................5 
1.1. 
Type/Design of Trial .....................................................................................................5 
1.2. 
Objective of Trials ........................................................................................................6 
1.3. 
Schematic Diagram of Trial Design .............................................................................7 
1.4. 
Schedule and Sequence of Procedures .........................................................................7 
2. 
GENERAL CONDUCT OF TRIAL ..........................................................................11 
2.1. 
Screening Period (Days –28 to –1) .............................................................................11 
2.2. 
Enrollment (Day 1) .....................................................................................................11 
2.3. 
Follow-up Visits FU 1-6 .............................................................................................12 
2.4. 
End of Study (EOS) Visit (FU 7) ...............................................................................13 
2.5. 
Additional Follow-Up Visits (FU 8-11, if needed) ....................................................14 
2.6. 
Assessment of Safety ..................................................................................................15 
2.6.1. 
Adverse Events ...........................................................................................................15 
2.6.2. 
Demographics and Medical History ...........................................................................15 
2.6.3. 
Vital Signs ..................................................................................................................15 
2.6.4. 
Electrocardiograms .....................................................................................................15 
2.6.5. 
Physical Examination .................................................................................................15 
2.6.6. 
Clinical Laboratory Assessments ...............................................................................15 
2.6.7. 
Anti-Inclisiran Antibodies ..........................................................................................16 
2.7. 
Assessment of Efficacy ...............................................................................................16 
2.7.1. 
Change in LDL-C .......................................................................................................16 
2.7.2. 
Change in Lipids/Lipoproteins ...................................................................................17 
2.8. 
Assessment of Pharmacogenetics ...............................................................................17 
3. 
ADVERSE EVENTS..................................................................................................18 
3.1. 
Adverse Event .............................................................................................................18 
3.2. 
AE Severity .................................................................................................................18 
3.3. 
Study Drug Causality ..................................................................................................18 
3.4. 
Serious Adverse Event ................................................................................................19 
3.5. 
Medication Errors .......................................................................................................19 
3.6. 
Adverse Events of Special Interest (AESIS) ..............................................................20 
4. 
MEASURES TO MINIMIZE/AVOID BIAS .............................................................20 


Inclisiran 
 
ORION-2 (MDCO-PCS-16-02) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
4
 
 
 
  
 
5. 
STATISTICAL PLAN................................................................................................21 
5.1. 
Sample Size ................................................................................................................21 
5.2. 
General Statistical Considerations and Definitions ....................................................21 
5.2.1. 
General Statistical Methods ........................................................................................21 
5.2.2. 
Analysis Population ....................................................................................................21 
5.2.2.1. 
Modified Intent-to-Treat (mITT) Population ..............................................................21 
5.2.2.2. 
Safety Population ........................................................................................................21 
5.2.3. 
Analysis Windows and Baseline ................................................................................22 
5.2.4. 
Missing data handling .................................................................................................22 
5.3. 
Statistical Analyses .....................................................................................................22 
5.3.1. 
Demographic and Baseline Characteristics ................................................................22 
5.3.2. 
Medical History ..........................................................................................................22 
5.3.3. 
Protocol Deviation ......................................................................................................22 
5.3.4. 
Study Drug Exposure ..................................................................................................22 
5.3.5. 
Concomitant Medications ...........................................................................................22 
5.3.6. 
Efficacy Analysis ........................................................................................................23 
5.3.6.1. 
Primary Efficacy Endpoints ........................................................................................23 
5.3.6.2. 
Secondary Efficacy Endpoints ....................................................................................23 
5.3.6.3. 
Exploratory Efficacy Endpoints .................................................................................23 
5.3.7. 
Safety Analysis ...........................................................................................................23 
5.3.7.1. 
Adverse Events ...........................................................................................................23 
5.3.7.2. 
Laboratory Tests .........................................................................................................24 
5.3.7.3. 
Vital Signs ..................................................................................................................24 
6. 
COMPUTER METHODS ..........................................................................................25 
7. 
CHANGES TO ANALYSES SPECIFIED IN THE PROTOCOL ............................26 
8. 
REFERENCES ...........................................................................................................27 
Appendix 1: Criteria for potentially clinically significant abnormal Lab Tests ............................28 
 
 


Inclisiran 
 
ORION-2 (MDCO-PCS-16-02) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
5
 
 
 
  
 
1. 
TRIAL DESIGN 
1.1. 
Type/Design of Trial  
This study will be a Phase II, open label, single arm, multicenter pilot study in subjects with 
homozygous familial hypercholesterolemia.  Informed consent (and written assent if subject is  < 
18 years of age) will be obtained from subjects before the initiation of any study-specific 
procedures.    
 
Subjects who meet study inclusion/exclusion criteria will be instructed to continue to follow a  
National Cholesterol Education Program (NCEP) Adult Treatment Panel III (or comparable) diet 
[Appendix C in protocol] and will be required to maintain their current lipid lowering drug 
therapy for the duration of the study.  
 
In this study, 8-10 subjects will be enrolled and receive open label inclisiran 300mg SC. Dosing 
interval will be determined by PCSK9 level at Day 60 or 90 or rate of change of PCSK9 levels 
between Days 60 and 90.   
 
On Day 1, eligible subjects will be enrolled and receive the first SC administration of inclisiran. 
After first study drug administration, the subject will be observed in the clinic for at least 4 hours 
post injection before being discharged. Subjects will return at Day 14 and Day 30 and then at 
monthly intervals. If a second dose of study drug is deemed necessary (if mean serum PCSK9 
levels are not suppressed by > 70% at Day 60 or 90, as compared to baseline), subjects will 
receive this dose at Day 90 or 104 respectively, based on PCSK9 levels from the previous visit.  
 
Study visits will include collection of AE and SAE data, vital signs, ECGs, concomitant 
medication, and laboratory tests. The study also includes collection of biomarker samples and, 
where approved by the independent ethics committee and/or institutional review board 
(IEC/IRB) and applicable regulatory and other authorities, all subjects will be invited to consent 
to pharmacogenetics analyses, unless underlying causal mutations of HoFH are well documented 
by a validated specialized laboratory.   
 
Efficacy assessments will include measurement of the effects of inclisiran on levels of LDL-C, 
other lipoproteins including total cholesterol (TC), triglycerides, high-density lipoprotein 
cholesterol (HDL-C), non-HDL-C, very low-density lipoprotein cholesterol (VLDL-C), 
apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), lipoprotein(a) [Lp(a)], and PCSK9.   
 
Formation of anti-drug antibodies (ADA) will be assessed on Day 1 (prior to and 4 hours after 
the injection) and on subsequent visits until the end-of-study (EOS).   
 
The EOS visit and the last estimation of lipids will occur at Day 180. Following Day 180 
subjects will continue in the study until the observed LDL-C reduction is less than 20% of the 
absolute reduction from baseline to Day 90. Subjects will be encouraged to complete all planned 
visits.   
 
The decision to initiate a Phase III study will be defined as an observed mean 15% or greater 
reduction in LDL-C. A number of factors may influence the proportion of subjects achieving this 


Inclisiran 
 
ORION-2 (MDCO-PCS-16-02) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
6
 
 
 
  
 
metric, in particular the specific LDL receptor mutation(s) or other causative mutations of HoFH 
studied. Given the small sample size for this part of the study, such issues will be taken into 
careful consideration prior to making the final decision.   
 
The safety/ tolerability and efficacy data from this study will be reviewed by a Safety Committee 
on an ongoing basis, and the results will be used to guide the decision to initiate a Phase III study 
in HoFH patients. A recommendation may be taken to stop or amend the study at any of these 
reviews.  
1.2. 
Objective of Trials  
Primary Objective(s): 
To characterize the effect of 90 and 180 days of subcutaneous inclisiran on the percentage 
change from Day 1 in low-density lipoprotein cholesterol (LDL-C) in subjects with homozygous 
familial hypercholesterolemia  
Secondary Objective(s): 
• 
To assess the effect of inclisiran on:  
– 
Change and percentage change in LDL-C from Day 1 to each subsequent visit 
until Day 180 or final visit  
– 
Change and percentage change in PCSK9  
– 
Change and percentage change in total cholesterol, triglycerides, HDLC, non-
HDL-C, VLDL-C, Apo-A1 Apo-B and Lp(a) from Day 1 to each subsequent visit 
until Day 180 or final visit  
• 
To evaluate the safety and tolerability of inclisiran in subjects with homozygous 
familial hypercholesterolemia  
Exploratory: 
           •      To evaluate the formation of Anti-drug antibodies (ADA) to inclisiran  
           •      To assess response of LDL-C by underlying causal mutations of HoFH 
 
 
 
 
 
 
 
 


Inclisiran 
 
ORION-2 (MDCO-PCS-16-02) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
7
 
 
 
  
 
1.3. 
Schematic Diagram of Trial Design 
 
The study design is presented in Figure 1 : 
Figure 1: 
Study Design 
 
1.4. 
Schedule and Sequence of Procedures 
The Schedule of Events/Assessments (Table 1) summarizes the study assessments by time point.  
This study consists of four periods:  Screening, Treatment, End of Study and Additional Follow-
up. 
•    The Screening period occurs prior to administration of study drug and consists of confirming 
eligibility.  
•    The Treatment period occurs from the time of enrolling the subject, collecting Day 1 
assessments and study drug administration through Day 90/104.  
•    The End of Study visit occurs at Day 180.  
•    The Additional Follow-up period (if necessary) occurs from end of study through Day 300.  
•    The maximum duration of a subject’s participation is from screening/informed consent to end 
of study (last follow-up) and is expected to be up to 328 days. 
 
 
 
 
 
 
 
 
 


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
8 
Schedule of Assessments 
Table 1: 
Study Design and Schedule of Assessments 
 
Screening  
Treatment Phas e  
End of 
Study 
(EOS)  
Additional Follow-Up 
p  
Study Day  
-28 to -1  
Day  
1  
FU1  
Day 14  
(± 2d)  
FU2  
Day 30  
(± 3d)  
FU3  
Day 60  
(± 3d)  
FU4  
Day 90  
(± 3d)  
Dose 2? a  
FU4X  
Day 104  
(± 3d)  
Dose 2? a  
FU5  
Day 120  
(± 3d)  
FU6  
Day 150  
(± 3d)  
FU7  
Day 180  
(± 3d)  
FU8 (Day 210) (± 3)  
FU9 (Day 240) (± 3)  
FU10 (Day 270) (± 3)  
FU11 (Day 300) (± 3)  
Informed consent  
X  
 
 
 
 
 
 
 
 
 
 
Medical History and 
prior meds  
X  
 
 
 
 
 
 
 
 
 
 
Physical Examination 
& full neurologic exam  
X  
 
 
 
 
 
 
 
 
X  
 
Inclusion / Exclusion 
Criteria  
X  
X  
 
 
 
 
 
 
 
 
 
Pharmacogenetic 
sample o  
X  
 
 
 
 
 
 
 
 
 
 
Enrollment  
X  
 
 
 
 
 
 
 
 
 
Vital Signs b  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
 
12 Lead ECG c  
X  
 
 
X  
 
Hematology,  
Coagulation d,  f  
X  
X 
X  
X  
X  
X  
X  
X  
X  
X  
X  
Biochemistry,  
Inflammatory markers 
d, f  
X  
X 
X  
X  
X  
X  
X  
X  
X  
X  
X  
HbA1c  
X  
X  
 
 
 
X  
 
 
 
X  
X n  
Urinalysis e,  
X  
X g 
 
 
X  
X  
Pregnancy test e, h  
X  
X h  
X  
X  
X  
X h  
X h  
X  
X  
X  
X i  


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
9 
ADA antibodies j  
X j, k  
 
X  
 
 
 
 
X k  
X k  
 X k  
Lipids / lipoproteins m  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Biomarker (stored 
samples)q  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Study drug admin  
 
X  
X a  
X a  
 
 
Concomitant 
medications  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
AE reporting  
 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
SAE reporting  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
 
ADA = anti-drug antibodies; AE = adverse event; ECG = electrocardiogram; FU=follow-up; EOS = end of study; hsCRP=high sensitivity C-reactive protein; 
IL6=interleukin 6; IFN-γ=interferon gamma; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9; SAE = 
serious adverse event; TNF-α=tumor necrosis factor alpha.  
  
a Day 104 visit only for those subjects who receive a second dose of study drug. Dose #2 may be given at 
Day 90 or 104 depending on PCSK9 levels as compared to baseline  
b Vital signs: blood pressure and heart rate will be measured prior to injection and at 4 hours after injection. c 
ECG is performed prior to the injection on Day 1.  
d Hematology, chemistry (including lactate, bicarbonate, glucose, HbA1c, liver and renal function, hsCRP, IL6, IFN-γ, and TNF-α), and coagulation testing. 
Blood samples for determination of laboratory values will be performed prior to study drug injection where relevant. All laboratory testing will be performed 
with subjects in a fasted state.   
e Lab tests performed in participating institution’s laboratory. Results must be available before the start of study drug injection on Day 1 to confirm subjects meet 
eligibility criteria.  
f Lab tests performed by study’s designated Central Lab facility from enrollment to EOS. In addition, subjects in whom LDL-C reduction is less than 20% of the 
absolute reduction from baseline to Day 90 will continue to be followed up on a monthly visit schedule either until this level has been reached or until Day 300.   
g Urinalysis collection is prior to the injection on Day 1. 
h Urine pregnancy test performed at each visit for females of childbearing potential. In addition, postmenopausal women who are less than 55 years of age will 
have a pregnancy test within 24 hours of enrollment and prior to any study drug injection.  Results must be available prior to the injection on Day 1 and, if a 
second dose of study drug is required, on Day 90/104.  
i Females of childbearing potential will have a pregnancy test at each additional follow-up visit until LDL-C reduction is less than 20% of the absolute reduction 
from baseline to Day 90.  


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
10 
j Two ADA samples will be drawn on Day 1: one before the injection and one 4 hours after the injection. k Additional aliquots of plasma and serum will be 
collected at each time point and stored for future analyses.  
l For subjects in whom LDL-C reduction is less than 20% of the absolute reduction from baseline to Day 90, formation of ADA will be assessed at the last visit. m 
Efficacy parameters (Lipids / lipoproteins) will include LDL-C, total cholesterol, triglycerides, HDL-C, non-HDL-C, very low-density lipoprotein (VLDL-C), 
apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), lipoprotein(a) [Lp(a)], and PCSK9.  
n Day 270 only.  
o Sample may be taken during screening or anytime during study to be processed and stored, but only after separate consent has been signed. p 
Additional Follow-Up visits only for those subjects in whom LDL-C reduction is less than 20% of the absolute reduction from baseline to Day 90.  
q 3 aliquots of plasma and 3 aliquots of serum will be stored for efficacy and safety biomarker analysis if needed. All samples will be destroyed 1 year following 
the last subject's last visit in the study.  
 
 
 
 
 
 
 
 
 
 
 
 


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
11 
2. 
GENERAL CONDUCT OF TRIAL 
Written informed consent will be obtained for this study by the principal investigator or sub 
investigator from all subjects before the performance of any protocol-specific procedure (if the 
subject is less than 18 years of age, written consent will be obtained from their guardian or 
legally authorized representative, with verbal assent from the child).   
2.1. 
Screening Period (Days –28 to –1) 
The following procedures will be performed within 28 days prior to enrollment:  
All screening laboratory tests will be analyzed at the Central Lab, with the exception of 
urinalysis and pregnancy test, which will be done in-house at the participating institution’s 
laboratory using the testing materials provided by the Central Lab.  The results of all 
screening laboratory tests should be reviewed prior to enrollment.  If these results confirm 
an exclusion criterion or suggest any contraindication to treatment with inclisiran, and/or 
other required ancillary medication(s), the subject must not be enrolled.  
1. Review of inclusion/exclusion criteria to confirm subject eligibility. 
2. Documentation of: 
a. Demography: age, gender and ethnic origin 
b. Medical history 
c. Concomitant medications 
3. Full physical examination including height, weight and full neurological examination 
(asdescribed in Protocol Appendix A ). 
4. Vital signs (blood pressure and heart rate). 
5. Blood samples drawn for screening clinical laboratory tests and results reviewed prior 
toenrollment.  All laboratory testing will be performed with subjects in a fasted state. 
a. Biochemistry 
b. Inflammatory markers 
c. Lipids/lipoproteins 
d. Hematology 
e. Coagulation 
f. HbA1c 
g. Biomarker (stored samples) 
h. Pharmacogenetics (stored samples, only if separate consent has been signed) 
6. Urinalysis (local), using standardized supplies from Central Lab. 
Urine pregnancy test (local), using standardized supplies from Central Lab, for females of 
childbearing potential. In addition, postmenopausal women who are less than 55 years of age 
must have a negative pregnancy test within 24 hours of enrollment. 
2.2. 
Enrollment (Day 1) 
Enrollment should only occur once subject eligibility is confirmed.   


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
12 
The following procedures will be performed prior to the injection of study drug:  
1. Review of inclusion/exclusion criteria 
2. Vital signs (blood pressure and heart rate will be measured prior to injection and at 4 
hours after injection) 
3. 12-lead ECG 
4. Blood samples drawn for clinical laboratory tests (Central Lab): 
a. Biochemistry 
b. Inflammatory markers 
c. Lipids/lipoproteins 
d. Hematology 
e. Coagulation 
f. HbA1c 
g. Anti-inclisiran (ADA) antibodies (prior to and 4 hours after the injection) 
h. Biomarkers (stored samples) 
5. Urinalysis (local) 
6. Urine pregnancy test (local), for females of childbearing potential. In 
addition,postmenopausal women less than 55 years of age will have a pregnancy test 
within 24 hours of enrollment.  Results must be available prior to the first injection of 
study drug 
7. Concomitant medications 
8. AE reporting 
9. SAE reporting 
10. Enrollment (only after subject eligibility is confirmed) 
If eligible, the subject will receive the first injection (SC) of study drug and will be 
observed in the clinic for at least 4 hours post-injection before being discharged. The site 
of injection is the abdomen. The injection site will be marked and mapped for later 
observation The following procedures will be performed 4 hours after the injection:  
11. Vital signs: blood pressure and heart rate 
12. Blood samples drawn for Anti-inclisiran (ADA) antibodies 
13. Concomitant medications 
14. AE reporting 
15. SAE reporting 
  
2.3. 
Follow-up Visits FU 1-6 
Subjects will return to the study center after study drug administration for Follow-Up Visits 
according to the Schedule of Events/Assessments (Table 1) until the end of the study.  
Procedures will be as follows:  


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
13 
1. Vital signs (blood pressure and heart rate will be measured prior to injection and at 4 
hours after injection) 
2. Blood samples drawn for clinical laboratory tests: 
a. Biochemistry 
b. Inflammatory markers 
c. Lipids/lipoproteins 
d. Hematology 
e. Coagulation 
f. HbA1c (only at Days 90 and 180 and Day 270 if applicable) 
g. Anti-inclisiran(ADA) antibodies (only at Day 30 and Day 150) 
h. Biomarkers (stored samples) 
3. Urine pregnancy test (local) for females of childbearing potential.  In addition, on Day 90 
or 104 (if a second dose of study drug is required), postmenopausal women less than 55 
years of age will have a pregnancy test and results must be available prior to the injection 
4. Concomitant medications 
5. AE reporting 
6. SAE reporting 
7. Study drug administration ONLY for subjects requiring a second dose of study drug 
(depending on the degree of suppression of serum PCSK9 as compared to baseline). 
If a second dose is deemed necessary, the subject will receive the injection (SC) at Day 90 or 
104, based on the PCSK9 levels from the previous visit. The site of injection is the abdomen (on 
the opposite side than the injection on Day 1).  The injection site will be marked and mapped for 
later observation. 
2.4. 
End of Study (EOS) Visit (FU 7) 
A subject’s participation in the study is complete when all procedures at the last study visit 
have been completed and all ongoing SAEs have been followed to resolution.  
 
Procedures will be as follows:  
1. Vital signs (blood pressure and heart rate)   
2. Physical examination (including full neurological examination as described in 
protocol Appendix A)  
3. 12-lead ECG  
4. Blood samples drawn for clinical laboratory tests:   
a. Biochemistry  
b. Inflammatory markers   
c. Lipids/lipoproteins   
d. Hematology   
e. Coagulation   
f. Anti-inclisiran (ADA) antibodies   


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
14 
g. Biomarkers (stored samples)  
5. Urinalysis (local)  
6. Urine pregnancy test (local) for females of childbearing potential  
7. Concomitant medications  
8. AE reporting  
9. SAE reporting  
2.5. 
Additional Follow-Up Visits (FU 8-11, if needed) 
These visits are only for those subjects in whom LDL-C reduction is less than 20% of the 
absolute reduction from baseline to Day 90. Procedures will be as follows:  
1. Blood samples drawn for clinical laboratory tests:   
a. Biochemistry  
b. Inflammatory markers   
c. Lipids/lipoproteins   
d. Hematology   
e. Coagulation   
f. HbA1c (only at Day 270)  
g. Anti-inclisiran (ADA) antibodies (only at last visit)  
h. Biomarkers (stored samples)  
2. Urinalysis (local)  
3. Urine pregnancy test (local). Females of childbearing potential will have a 
pregnancy test at each additional follow-up visit until LDL-C reduction is less than 
20% of the absolute reduction from baseline to Day 90  
4. Concomitant medications  
5. AE reporting  
6. SAE reporting  
 
 
 
 
 
 
 


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
15 
2.6. 
Assessment of Safety 
2.6.1. 
Adverse Events  
Subjects will be carefully monitored for adverse events by the investigator during the designated 
study period (See Section 3). 
2.6.2. 
Demographics and Medical History 
 
Baseline demographic information will be collected during screening, and will include age, sex 
and race/ethnicity.  
Relevant medical history includes all ongoing medical or surgical issues. Remote medical and 
surgical history > 5 years from the time of screening should only be included if considered 
relevant to the study. 
2.6.3. 
Vital Signs 
Vital Signs include heart rate and blood pressure 
2.6.4. 
Electrocardiograms 
12-Lead ECGs will be collected at Day 1 and at the Day 180 visit only, unless clinically 
indicated. 
2.6.5. 
Physical Examination 
The physical examination should include a focused examination, which may include general, 
respiratory, cardiovascular, abdominal, extremities, and recording of height, weight.  
The physical examination should also include a full neurologic evaluation as described in 
Appendix A of protocol. 
2.6.6. 
Clinical Laboratory Assessments 
Specimens will be obtained at the time points in the Schedule of Assessments (Table 1). 
Additional aliquots of plasma or serum will be collected at each time point and stored for any 
clinically indicated efficacy or safety analyses to be conducted at the end of the study.   
Subjects will be in a fasted state for all clinical laboratory assessments. Screening lab tests will 
be performed by the Central Lab, with the exception of urinalysis and pregnancy test, which will 
be done in-house at the participating institution’s laboratory using testing materials supplied by 
the Central Lab. Results from these screening tests must be available before the start of study 
drug injection on Day 1 to confirm subjects meet eligibility criteria.  
Laboratory assessments will include:   
Biochemistry: AST, ALT, alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), uric 
acid, total bilirubin (TBIL), direct bilirubin, indirect bilirubin, lactate, bicarbonate, sodium, 
creatine kinase (CK), albumin, total protein urea (BUN), creatinine, potassium, chloride, glucose 
(fasting), inorganic phosphate, eGFR, calcium, and tryptase (as required). 
Inflammatory markers: hsCRP (fasting), IL6, IFN-γ, and TNF-α  


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
16 
Hematology: hemoglobin, hematocrit, erythrocytes, reticulocytes, platelet counts, mean cell 
hemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin 
concentration (MCHC), white blood cell count, differential blood count. 
Coagulation: prothrombin time (PT), international normalized ratio (INR), activated partial 
thromboplastin (aPTT).  
HbA1c: hemoglobin A1c  
Urinalysis: Urinalysis will be performed at the time points defined in the Schedule of 
Assessments and evaluated by dipstick analyses at the investigational site local lab (a 
standardized dipstick test will be supplied by the Central Lab). Urinalysis will be performed 
from a sample of mid-stream urine. In case of abnormal results, microscopy and other 
assessments will be performed at the local lab. The following parameters will be assessed: 
Nitrite, protein, glucose, ketone, urobilinogen, bilirubin, red blood cells (RBC)/erythrocytes, 
white blood count (WBC)/leukocytes, pH, urine sediment (microscopic examination will be 
performed in the event of abnormalities).  
Urine pregnancy: Urine pregnancy testing will be conducted locally at the visits specified in the 
Schedule of Assessments (a standardized pregnancy test will be supplied by the Central lab). 
2.6.7. 
Anti-Inclisiran Antibodies 
Additional sample for analysis of the induction of antibodies will be collected at the time points 
in the Schedule of Assessments (Table 1).   
Aliquots of serum samples will be obtained and frozen, to permit future analysis of the effect of 
inclisiran on the expression of these exploratory biomarkers. Biological samples for biomarker 
research will be retained on behalf of the Sponsor for one year following the last subject's last 
visit in the study.  
2.7. 
Assessment of Efficacy 
Specimens for assays of lipids/lipoproteins will be obtained at the time points in the Schedule of 
Assessments (Table 1). Subjects will be in a fasted state for all efficacy laboratory assessments. 
Parameters to be assessed will include: total cholesterol (TC), triglycerides, LDL-C, HDL-C, 
non-HDL-C, very low-density lipoprotein (VLDL-C), apolipoprotein A1 (Apo-A1), 
apolipoprotein B (Apo-B), lipoprotein(a) [Lp(a)], and PCSK9. 
2.7.1. 
Change in LDL-C 
The primary efficacy endpoint is the percentage change in LDL-C at Day 90 and Day 180.   
In addition, this study will assess change and percentage change in LDL-C from Day 1 to each 
subsequent visit until Day 180 or final visit as a secondary efficacy endpoint .  
Blood samples for determination of LDL-C (β-quantification) concentrations will be collected at 
the time points in the Schedule of Assessments.  


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
17 
2.7.2. 
Change in Lipids/Lipoproteins 
Secondary efficacy assessments will include measurement of the effects of inclisiran on levels of 
lipids and lipoproteins including total cholesterol, triglycerides, LDL-C, HDL-C, non-HDL-C, 
VLDLC, Apo-A1, Apo-B, Lp(a), and PCSK9.   
 
• 
Change and percentage change in PCSK9 levels   
• 
Change and percentage change in other lipids, and apolipoproteins   
• 
Biomarkers (stored samples): Additional aliquots of plasma and serum will be 
collected at each time point and stored for additional analyses, including future 
analysis of biomarkers of CV risk. These samples will be retained for 1 year 
following the last subject's last visit in the study.  
Plasma samples will be analyzed using a validated enzyme linked immunosorbent assay to 
determine PCSK9 protein concentration. Full details of the analytical methods used will be 
described in a separate bioanalytical report.   
2.8. 
Assessment of Pharmacogenetics 
A blood sample will be collected, preferably during screening, only from subjects who sign a 
separate consent for pharmacogenetics. Samples will be processed as described in the Laboratory 
Manual and stored. Genetic assessment will be performed by an accredited laboratory. This 
assessment will determine if there is a different response for LDL-C lowering based on the type 
of mutation(s). 


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
18 
3. 
ADVERSE EVENTS 
3.1. 
Adverse Event 
Adverse Event (AE): Any untoward medical occurrence in a patient or clinical trial subject 
administered a medicinal product and which does not necessarily have a causal relationship with 
this treatment. An adverse event can therefore be any unfavorable and unintended sign (eg, an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal product.   
Planned hospital admissions and/or surgical operations for an illness or disease that existed 
before the study drug was given or the subject was randomized in a clinical study are not to be 
considered AEs.  
Adverse events or abnormal test findings will be followed until the event (or its sequelae) or the 
abnormal test finding resolves or stabilizes at a level acceptable to the Sponsor/Investigator. 
3.2. 
AE Severity 
The severity of an AE will be assessed by the investigator. The investigator should ensure that 
any subject experiencing an AE receives appropriate medical support until the event resolves. 
Adverse events will be graded on a 3-point scale and reported as indicated on the case report 
form. The intensity of an AE is defined as follows: 
1 = Mild: Discomfort noticed, but no disruption to daily activity. 
2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity. 
3 = Severe: Inability to work or perform normal daily activity. 
3.3. 
Study Drug Causality 
The relationship of an AE to study treatment will be assessed with consideration to the following 
criteria: 
 Temporal relationship to the initiation of study medication 
 Response of the event to withdrawal of study medication 
 AE profile of concomitant therapies 
 Clinical circumstances during which the AE occurred 
 Subject’s clinical condition and medical history  
Categorization of causality will be designated by the investigator as stated below: 
Reasonable possibility - There are facts (evidence) or arguments to suggest a causal 
relationship between the event and the IMP. 
No reasonable possibility – There are few to no facts (evidence) or arguments to suggest 
a causal relationship between the event and the IMP 


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
19 
3.4. 
Serious Adverse Event 
A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 
• 
Results in death,  
• 
Is life-threatening, i.e., the subject was, in the opinion of the investigator, at 
immediate risk of death from the event as it occurred (it does not include an 
event that, had it occurred in a more severe form, might have caused death),  
• 
Results in a significant, persistent or permanent change, impairment, damage or 
disruption in the subject's body function/structure, physical activities and/or 
quality of life,  
• 
Requires in-subject hospitalization or prolongs hospitalization,  
• 
Is a congenital anomaly/birth defect, or  
• 
Is another medically significant event where medical and scientific judgement 
should be exercised in deciding whether other situations should be considered 
serious reactions, such as important medical events that might not be 
immediately life threatening or result in death or hospitalization but might 
jeopardize the subject or might require intervention to prevent one of the other 
outcomes listed above. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization or development of dependency 
or abuse. Any suspected transmission via a medicinal product of an infectious 
agent is also considered a serious adverse reaction.  
A distinction should be drawn between serious and severe AEs. Severity is an estimate or 
measure of the intensity of an AE, while the criteria for serious AEs are indications of adverse 
subject outcomes for regulatory reporting purposes. A severe AE need not necessarily be 
considered serious and a serious AE need not be considered severe. For example, nausea that 
persists for several hours may be considered severe nausea, but not an SAE. On the other hand, 
an MI that may be considered minor could also be an SAE if it prolonged hospitalization. 
3.5. 
Medication Errors 
Medication error refers to any unintended error in the dosing and administration of the study 
product as per instructions in the protocol. Medication Errors generally fall into four categories 
as follows:  
1. 
Wrong study drug 
2. 
Wrong dose (including dosing regimen, strength, form, concentration, amount, 
including above the maximum or under the minimum recommended dose); 
3. 
Wrong route of administration; 
4. 
Wrong patient (i.e., not administered to the intended subject) 


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
20 
3.6. 
Adverse Events of Special Interest (AESIS) 
An adverse event of special interest (serious or nonserious) is one of scientific and medical 
concern specific to the Sponsor’s study drug or program, which warrants ongoing monitoring 
and rapid communication by the investigator to the sponsor. Such an event might warrant further 
investigation in order to characterize and understand it.  
The following AESI(s) have been identified for the study drug inclisiran in this protocol. • 
Injection site reactions (ISR)  
Injection site reactions including individual signs or symptoms at the injection site reported 
following study drug administration will be collected as an AESI. 
The grade (severity) of injection site reaction will be determined by the Common Terminology 
Criteria for Adverse Events (CTCAE) criteria of Injection Site Reaction (General disorders and 
administration site conditions) (see Table 2). 
Table 2: 
Common Terminology Criteria for Adverse Events (CTCAE) criteria of 
Injection Site Reaction 
Grade I: 
Tenderness with or without associated symptoms (eg, warmth, erythema, 
itching) 
Grade II: 
Pain; lipodystrophy; edema; phlebitis 
Grade III 
Ulceration or necrosis; severe tissue damage; operative intervention indicated 
Grade IV 
Life-threatening consequences; urgent intervention indicated 
Grade V 
Death  
Abbreviations: AE = adverse even 
Reference source: Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0, Published May 28, 2009 
4. 
MEASURES TO MINIMIZE/AVOID BIAS 
This is an unblinded, open label study.  The primary endpoint is based on an assessment of LDL-
C, which is a measurement that is not likely to be subject to interpretation bias   


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
21 
5. 
STATISTICAL PLAN 
This is an 8-10 subject non-randomized pilot study. Subjects with homozygous familial 
hypercholesterolemia will be recruited from approximately 5 sites globally.  Subjects that qualify 
for entry into the study will be enrolled to receive inclisiran.  The primary objective of this study 
is to characterize the effect of 90 and 180 days of subcutaneous inclisiran on the percent change 
from Day 1 in low-density lipoprotein cholesterol (LDL-C) in subjects with homozygous familial 
hypercholesterolemia.    
The primary hypothesis is that inclisiran, when used in combination with maximally tolerated 
statin therapy with or without ezetimibe, will be well-tolerated, will suppress circulating PCSK9 
>70% and will result in reduction of LDL-C, defined as mean percent change from Day 1 
following 90 and 180 days of treatment, in subjects with homozygous familial 
hypercholesterolemia. 
5.1. 
Sample Size 
The sample size was chosen based on clinical considerations. 
5.2. 
General Statistical Considerations and Definitions  
5.2.1. 
General Statistical Methods 
All study-collected data will be summarized by treatment group using descriptive statistics, 
graphs, and/or raw data listings. Categorical variables will be summarized using counts and 
percentages. Percentages are based on the number of subjects in the analysis set for whom there 
are non-missing data, unless otherwise specified. Continuous variables, including changes from 
day 1, will be summarized using descriptive statistics (n, mean, standard deviation [SD], median 
and interquartile range [first and third quartiles], minimum and maximum). All summaries are 
presented for all subjects due to the small sample size in this study. 
The Statistical Analysis Plan (SAP) will be finalized before database lock.  
Statistical analyses will be carried out using SAS statistical analysis software version 9.2 or 
higher (SAS Institute, Inc., Cary, North Carolina, USA). 
5.2.2. 
Analysis Population 
The following populations will be used for data analyses and/or presentation. 
5.2.2.1. 
Modified Intent-to-Treat (mITT) Population 
All ITT subjects (who receive at least one dose of study drug), who have baseline and at least 
one post-baseline measurement for the primary endpoint.  This will be the primary population for 
the efficacy analyses; unless specified otherwise, the mITT will be the default analysis set in this 
study. 
5.2.2.2. 
Safety Population 
All subjects who received at least one dose of study drug. Treatment classification will be based 
on the actual treatment received. This will be the primary population for the safety analyses.  


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
22 
The primary analysis set is the modified Intent-to-Treat (mITT), which will include all enrolled 
subjects who have received at least one dose of study drug. Unless specified otherwise, the mITT 
will be the default analysis set in this study. 
5.2.3. 
Analysis Windows and Baseline 
The observational period for the study includes the screening period (Day -28 to Day -1), 
treatment and follow up period (Day 1 to Day 180), additional follow up period (up to Day 300, 
subject will continue in the study until the observed LDL-C reduction is less than 20 % of the 
absolute reduction from baseline to Day 90). Any event occurring beyond the defined 
observational period, even if collected on the CRF, will not be included in the planned statistical 
analysis.  However, all data, including that reported after the defined observational period, will 
be included in the subject data listings.    
Unless otherwise specified, for evaluations that are collected at multiple occasions prior to 
initiation of study drug administration, the latest evaluation will be considered the "Baseline" 
evaluation for analysis. 
5.2.4. 
Missing data handling 
Unless otherwise specified, missing data will not be imputed and will be excluded from the 
associated analysis. 
5.3. 
Statistical Analyses 
5.3.1. 
Demographic and Baseline Characteristics 
Subject demographics (age/age group, gender, weight, height, body mass index, race, enthnicity, 
and country) and confirmation on HoFH (yes, no) at baseline will be summarized using the 
mITT and safety populations. 
5.3.2. 
Medical History 
Medical history(targeted and other medical history) data collected in the eCRFs will be 
summarized using the mITT and safety populations.  
5.3.3. 
Protocol Deviation 
Subjects with protocol deviation(s) will be listed. 
5.3.4. 
Study Drug Exposure 
Study drug administration including actual dose injected, time for injection, and missed doses 
will be listed. 
5.3.5. 
Concomitant Medications  
Summary of concomitant (Day 1 or later) medication will be provided.  [Medication will be 
coded with WHO drug dictionary]. Subjects will be counted only once within each period by 
medication. A listing for all prior (pre Day 1) and concomitant medications will be provided. 


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
23 
5.3.6. 
Efficacy Analysis  
5.3.6.1. 
Primary Efficacy Endpoints 
The primary endpoint is the percent change in LDL-C following 90 and 180 days of treatment.  
Summary statistics and 95% CI of this primary endpoint will be provided. Changes of LDL-C 
from Day 1 by scheduled visits will also be summarized. Response rate of subjects with 15% or 
greater reduction in LDL-C from Day 1 following 90 and 180 days of treatment will be 
calculated.  
The analysis for the primary endpoint will be descriptive. Means and confidence intervals will be 
provided. Mean plots with standard error bars will be provided for observed LDL-C value, 
change in LDL-C value, and percent change in LDL-C value. 
5.3.6.2. 
Secondary Efficacy Endpoints 
Analyses of secondary efficacy endpoints will be similar to the primary analysis of the primary 
endpoint. 
The secondary endpoints of this trial are: 
 Change and Percentage change in LDL-C from Day 1 to each subsequent visit until 
Day 180 or final visit 
 Change and Percentage change in PCSK9 from Day 1 to each subsequent visit until 
Day 180 or final visit 
 Change and Percentage change in total cholesterol, triglycerides, HDLC, non-HDL-
C, VLDL-C, Apo-A1 Apo-B and Lp(a) from Day 1 to each subsequent visit until Day 
180 or final visit 
5.3.6.3. 
Exploratory Efficacy Endpoints 
The exploratory endpoints of this trial are: 
 Formation of Anti-drug antibodies (ADA) to inclisiran 
 Response of LDL-C by the causal genetic mutations of HoFH  
5.3.7. 
Safety Analysis 
Safety summaries will include the incidence of adverse events, summaries of laboratory 
parameters (including shift tables), vital signs, ECGs and anti-drug antibodies. 
5.3.7.1. 
Adverse Events 
The Medical Dictionary for Regulatory Activities (MedDRA) dictionary will be used for coding 
AEs. An AE (classified as preferred term) occurring during the treatment period will be counted 
as a treatment emergent AE (TEAE) either if it is not present at day 1 or if it is present at day 1 
but increased in severity during the treatment period. 


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
24 
The number (percentage) of subjects reporting TEAEs/Serious TEAEs will be tabulated by 
system-organ class, and preferred term. If more than one event occurred with the same preferred 
term for the same subject, the subject will be counted only once for that preferred term. 
Subject listing on AEs/SAEs/AEs leading to a discontinuation or death will be presented. 
5.3.7.2. 
Laboratory Tests 
Laboratory values will be summarized, including changes and percent changes from baseline at 
each time point. Analyses will also be performed for pertinent lab parameters (Appendix 1) for 
incidence rates of potentially clinical significant values for subjects without potentially clinical 
significant value at baseline.  
In addition, subjects with clinically significant laboratory values (Table 3) will be listed. 
 
 
 
5.3.7.3. 
Vital Signs 
Change from baseline in vital signs will be summarized descriptively at each scheduled time 
point. 


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
25 
6. 
COMPUTER METHODS 
Statistical analyses will be performed using SAS (version 9.2 or later version). 


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
26 
7. 
CHANGES TO ANALYSES SPECIFIED IN THE PROTOCOL 
There are no changes to the analyses specified in the protocol. 


Inclisiran 
 
  MDCO-PCS-16-02 (ORION-2) 
The Medicines Company 
 
16.1.9 Statistical Analysis Plan 
Confidential 
 
27 
8. 
REFERENCES 
1. Protocol MDCO-PCS-16-02 Amendment 1.0, 7 Nov 2016 
2. Protocol MDCO-PCS-16-02 Amendment 2.0, Netherlands Specific, 18 April, 2017